## Supplementary Table I

Therapy	Study title	Chemotherapy	Radiation therapy	Clinical trials identifier
Checkpoint inhibitor	18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody Combined With First-line Chemotherapy in Advanced Non-small Cell Lung Cancer	Y		https://ClinicalTrials.gov/show/NCT04996927
Checkpoint inhibitor	A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy	Y		https://ClinicalTrials.gov/show/NCT04151563
Checkpoint inhibitor	A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With	Y		https://ClinicalTrials.gov/show/NCT04139135
·	Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in			
Checkpoint inhibitor	Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With HLX04 and Chemotherapy	Y		https://ClinicalTrials.gov/show/NCT04150575
Checkpoint inhibitor	(XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)	Y		https://ClinicalTrials.gov/show/NCT04547166
Checkpoint inhibitor	A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)	Y		https://ClinicalTrials.gov/show/NCT03958890
Checkpoint inhibitor	A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer	Y	Y	https://ClinicalTrials.gov/show/NCT02125461
Checkpoint inhibitor	A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma the POTENTIAL Study	Y		https://ClinicalTrials.gov/show/NCT04814069
Checkpoint inhibitor	A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENRTL)	Y		https://ClinicalTrials.gov/show/NCT04365036
Checkpoint inhibitor	A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors	Y		https://ClinicalTrials.gov/show/NCT05235542
Checkpoint inhibitor	A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC	Y		https://ClinicalTrials.gov/show/NCT03817658
Checkpoint inhibitor	A Phase II Study to Test the Efficacy of AB928 (Dual Adenosine Receptor Antagonist) and AB122 (a PD1 Checkpoint Inhibitor) in Combination With Short Course Radiotherapy and Consolidation Chemotherapy for Rectal Cancer.	Y		https://ClinicalTrials.gov/show/NCT05024097
Checkpoint inhibitor	A Phase II Trial of Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma	Y		https://ClinicalTrials.gov/show/NCT02844075
Checkpoint inhibitor	A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in	Y		https://ClinicalTrials.gov/show/NCT04806945
Checkpoint inhibitor	Patients With Advanced Cervical Cancer A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations	Y		https://ClinicalTrials.gov/show/NCT05157776
Checkpoint inhibitor	A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy	Y		https://ClinicalTrials.gov/show/NCT03076554
Checkpoint inhibitor	A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Pacifizace) in Patients With Stage IIIB/IIII or IV NSCLC	Y		https://ClinicalTrials.gov/show/NCT04033354
Checkpoint inhibitor	A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin-Eloposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)	Y		https://ClinicalTrials.gov/show/NCT04063163
Checkpoint inhibitor	A Study Comparing Abzolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple-Negative Breast Cancer	Y		
Checkpoint inhibitor	A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma		Y	https://ClinicalTrials.gov/show/NCT02866747
Checkpoint inhibitor	A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma	Y		https://ClinicalTrials.gov/show/NCT04568304
Checkpoint inhibitor	A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment	Y		https://ClinicalTrials.gov/show/NCT03522246
Checkpoint inhibitor	Following Response to Front-Line Platinum-Based Chemotherapy  A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell	Y		https://ClinicalTrials.gov/show/NCT04460066
Checkpoint inhibitor	Carcinoma.  A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in	Y		https://ClinicalTrials.gov/show/NCT01633970
·	Participants With Locally Advanced or Metastatic Solid Tumors  A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or			-
Checkpoint inhibitor	Metastatic Urothelial Bladder Cancer [IMvigor211]  A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After	Y		https://ClinicalTrials.gov/show/NCT02302807
Checkpoint inhibitor	A study of Alezonizuman Compared with Dicease in Non-Small Cell Lung Cancer (NSCLC) Aller Failure With Platinum-Containing Chemotherapy	Y		https://ClinicalTrials.gov/show/NCT02813785
Checkpoint inhibitor	A Study of Alezolizumab Compared With Platinum Doublet Chemotherapy for PD-L1 Highly Expressed, Chemotherapy-Naive Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer	Y		https://ClinicalTrials.gov/show/NCT05047250
Checkpoint inhibitor	A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)	Y		https://ClinicalTrials.gov/show/NCT02657434
Checkpoint inhibitor	A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)	Y		https://ClinicalTrials.gov/show/NCT04767295
Checkpoint inhibitor	A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer	Y	Y	https://ClinicalTrials.gov/show/NCT04974827
Checkpoint inhibitor	Patients Treated With Chemoradiotherapy	Y		https://ClinicalTrials.gov/show/NCT04749394
Checkpoint inhibitor	A Study of Carboplatin-Pacitiaxel/Nab-Pacitiaxel Chemotherapy With or Without Pembrolizumab (MK- 3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475- 407/KEYNOTE-407)	Y		https://ClinicalTrials.gov/show/NCT02775435
Checkpoint inhibitor	A Study of Carboplatin-Pacilitaxel/Nab-Pacilitaxel Chemotherapy With or Without Pembrolizumab (MK- 3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475- 407/KEYNOTE-407)-China Extension Study	Y		https://ClinicalTrials.gov/show/NCT03875092
Checkpoint inhibitor	A Study of Carilizumab Combined With Concurrent Chemoradiotherapy  A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell	Y		https://ClinicalTrials.gov/show/NCT05151549
Checkpoint inhibitor Checkpoint inhibitor	A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer	Y	Y	https://ClinicalTrials.gov/show/NCT02759575 https://ClinicalTrials.gov/show/NCT03904537
·	A Study of Combination of Ami-PD1 Antibody-activated Ills and Chemotherapy in Colorectal Cancer A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers	Y	Y	https://ClinicalTrials.gov/show/NCT0390453/ https://ClinicalTrials.gov/show/NCT04892875
Checkpoint inhibitor	A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-	Y	Y	https://ClinicalTrials.gov/show/NCT04636762
Checkpoint inhibitor	Stage (ES) Small Cell Lung Cancer (SCLC) A Study of Dato-DX4 Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1	Y		https://ClinicalTrials.gov/show/NCT05374512
Checkpoint inhibitor	Inhibitor Therapy (TROPION-Breast02)  A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone		Y	https://ClinicalTrials.gov/show/NCT03196401
Checkpoint inhibitor	Plasmacytoma A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With	Y		https://ClinicalTrials.gov/show/NCT03085914
Checkpoint inhibitor	Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)  A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First	Y		https://ClinicalTrials.gov/show/NCT04976647
	Line sqNSCLC  A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based			
Checkpoint inhibitor	A Study of Nivollumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or	Y		https://ClinicalTrials.gov/show/NCT03597295
Checkpoint inhibitor	A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants with Advanced or Metastatic Gastric Cancer  A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in	Y		https://ClinicalTrials.gov/show/NCT05165264
	IC ORGAN OLI SIMDIONIZUMAD MINI-047 OLIN COMDINAMON WINI CHEMOTRETADY OF IMMUNOTRETADY IN	Y	l .	https://ClinicalTrials.gov/show/NCT02039674
Checkpoint inhibitor	Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)  A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus	T		

Content   Cont		A Study of Radiation Therapy With Pembrolizumab and Olaparib in Women Who Have Triple-Negative			
Content	Checkpoint inhibitor	Breast Cancer		Y	https://ClinicalTrials.gov/show/NCT04683679
Consequent   Continue   Continu	Checkpoint inhibitor		Υ		https://ClinicalTrials.gov/show/NCT04927884
Consequent Control	Checkpoint inhibitor		Υ		https://ClinicalTrials.gov/show/NCT04856176
Comparison with   Surgive Settlemen Fine Commonstrate Research Engineer in Fragmany of Common Street   Commo	Checkpoint inhibitor	A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or	Y		https://ClinicalTrials.gov/show/NCT03092895
Condescription   April of the Times and Embry Chameles (Control Processes)   Control Processes (Control Processes)   Control				Y	
Changes and Sections   Apentions   Apent					
Changes and Sections   Apentions   Apent		A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus			
Checkpost in bilbins  Analys of Transcription (ECA-457) Peace Commonitoring Followers) is followers between processors in proces	Checkpoint inhibitor	Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA	Υ		https://ClinicalTrials.gov/show/NCT04267237
Non-your Canada					
Conditional Continues   Cont	Checkpoint inhibitor		Υ		https://ClinicalTrials.gov/show/NCT03745222
Control (1985)	Checkpoint inhibitor		Y		https://ClinicalTrials.gov/show/NCT03430843
Consequent (Ambala Control C					
Conception   PUTC ground with Authorized in Management (Continue)   Put   Pu	Checkpoint inhibitor	Esophageal Squamous Cell Carcinoma.	Y		nttps://ClinicalTrials.gov/snow/NC104084158
Conceptombase Control	Checkpoint inhibitor		Υ		https://ClinicalTrials.gov/show/NCT05152147
Chestagons inhabits	Checkpoint inhibitor		Υ		https://ClinicalTrials.gov/show/NCT03594747
Fig. C. 1 miles   Trace   Fig. C. 2 miles   Trace   Fig. C. 2 miles   Trace	0				Lucy (CD) in IT is to a file a NOTO 1005 110
Chescopies inhibits	Checkpoint inhibitor		Y		nttps://ClinicalTrials.gov/snow/NC104995419
Cateograph inhabits   Cate   Inhabits   Inhabit	Checkpoint inhibitor		~		https://ClinicalTrials.gov/show/NCT05216237
Section (1985)  Checkpoint inhibitation  Checkpoint inhibitation  A Trial of Public Park (1985)  Checkpoint inhibitation  Checkpoint inhibitation  Checkpoint inhibitation  A Trial of Public Park (1985)  Checkpoint inhibitation  A Trial of Public Park (1985)  Checkpoint inhibitation  Checkpoint i	Спескропт ппириог	Gastroesophageal Junction (GEJ) Cancer	'		Imps.//Clinical mais.gov/snow/NC 1032 10237
Seption in abible	Checkpoint inhibitor		Υ		https://ClinicalTrials.gov/show/NCT03197935
Cheegoministics A Trial Evaluation State Institute Consistance for Patients With Notice Control Contro	Checkpoint inhibitor	A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving	Υ		https://ClinicalTrials.gov/show/NCT04306042
Checkpoint inhibitor  An of GPT 1916 In Combination With Toughton Activation In Combination Vity Toughton International Committed Commit	Checknoint inhibitor	A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC		Υ	
A Flad of EPRIVED in Combination With Programmab and Concurrent Chemocordomorphy in Stage III   V   Imput Chemocordomorphy in Stage III   No. 00   Imput Chemocordomorphy in Stage III   V   Imput Chemocordomorphy III   V   Imput Chem				1	*
All Control (CROPK) Control (CROPK) on Combination VM. Austrands C. Cross Control (CROPK)   V   Imput Chimical Trials growthown CTD3451500		A Trial of GFH018 in Combination With Toripalimab and Concurrent Chemoradiotherapy in Stage III			
A Total of Preferenciasions in Combination With Chemotherapy in Registration (CVID) 27.79 (ACM) 12.79 (ACM) 12.7					
Checkpoint inhibitor		A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC	Υ		https://ClinicalTrials.gov/show/NCT03631784
Cenerosciolenterpy in the Treatment of High risk Raspophanygeal Carcinoma  Checksport inhibits  Checksport inhibits  Chacksport inhibits  AND Checksport inhibits  AND Checksport inhibits  AND Checksport inhibits  Checksport inhibits  AND Checksport inhibits  Ch	Checkpoint inhibitor	A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC	Υ		https://ClinicalTrials.gov/show/NCT04316364
Checkgonit inhibits	Checkpoint inhibitor		Υ		https://ClinicalTrials.gov/show/NCT04557020
December inhibits	Checkpoint inhibitor	Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative	Υ		https://ClinicalTrials.gov/show/NCT02685059
Cineciporit inhibitor Checiporit inhibitor Checipor	Checkpoint inhibitor		Y		
Checkpoint inhibiter   Minister	Checkpoint inhibitor		Υ		https://ClinicalTrials.gov/show/NCT05383482
Chedopoint inhibitor Final-Lamin Temporary to Stage Nor Price count PO-1.1.1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Industry of Stage Nor Price count PO-1.1.2 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Industry of County of Stage Nor Price County of Nor Price County of Stage Nor Price County of Nor Price Coun		AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer	Υ		
First-Line Therapy to Stage No rifecument PDL-11 Non-Small Cell Lung Canner (CheckMala 026)  Checkpoint Inhibitor  And Control Chemotherapy For Extensive Stage Small Cell Lung Cancer A Single Arm Study  Checkpoint Inhibitor  And PD-1 Anabody Nith Russialization Therapy in Patients With HERC-regulate Medication Chemotherapy For Extensive Stage Small Cell Lung Cancer A Single Arm Study  Y https://clinicalTriats.gov/inhow/NCT04228617  Checkpoint Inhibitor  And PD-1 Anabody Nith Russialization Therapy in Patients With HERC-regulate Medicate Extensic Cancer  Y https://clinicalTriats.gov/inhow/NCT04228617  Checkpoint Inhibitor  And PD-1 Anabody Nith Russialization Therapy in Patients With HERC-regulate Medicate Extensic Cancer  Y https://clinicalTriats.gov/inhow/NCT04179888  Checkpoint Inhibitor  And PD-1 Anabody Alone or in Combination With Chemotherapy in Relapsed or Refractory  Y https://clinicalTriats.gov/inhow/NCT04179888  And PD-1 and Note Office Regulate Victory Chemotherapy Combined With Radiotherapy in Relapsed or Refractory  Y https://clinicalTriats.gov/inhow/NCT0281101  And-PD-1 and Note Office Regulate Victory Chemotherapy Combined With Radiotherapy in Relapsed or Refractory  And-PD-1 and Note Office Regulate Victory Chemotherapy Combined With Radiotherapy in Relapsed or Refractory  And-PD-1 Anabody Alone or in Combination With Decisionin-Chemotherapy in Relapsed or Refractory  And-PD-1 Anabody Alone or in Combination With Decisionin-Chemotherapy in Relapsed or Refractory  And-PD-1 Anabody Alone or in Combination With Decisionin-Chemotherapy in Relapsed or Refractory  And-PD-1 Anabody Alone or in Combination With Decisionin-Chemotherapy in Relapsed or Refractory  And-PD-1 Anabody Alone or in Combination With Decisionin-Chemotherapy in Relapsed or Refractory  And-PD-1 Anabody Alone or in Combination With Decisionin-Chemotherapy in Relapsed or Refractory  And-PD-1 Anabody Alone or in Combination With Chemotherapy in Relapsed or Refractory  And-PD-1 Anabody Alone or in Combination With Chemotherapy in Relaps				Y	
Induction Chemotherapy For Extensive Stage Small Cell Lung Cancor A Single Arm Study  Checkpoint inhibitor  And IPD-1 Antibody in Standard Chemotherapy For Extensive Stage Small Cell Lung Cancor A Single Arm Study  Antibory Lung Chemotherapy For Extensive Stage Small Cell Lung Cancor A Single Arm Study  Antibory Lung Chemotherapy For Extensive Stage Small Cell Lung Cancor A Single Arm Study  Antibory Lung Chemotherapy For Extensive Stage Small Cell Lung Cancor Chemotherapy In Patients With Ett2-registry Metastatis (Breast Cancor  Anti-PD-1 and mCDF Followed by Chemorhacidorine pay in Patients With Sign III Squamous Cell Anal  Anti-PD-1 and mCDF Followed by Chemorhacidorine pay in Patients With Sign III Squamous Cell Anal  Anti-PD-1 and mCDF Followed by Chemorhacidorine pay in Patients With Sign III Squamous Cell Anal  Anti-PD-1 and mCDF Followed by Chemorhacidorine pay in Patients With Sign III Squamous Cell Anal  Anti-PD-1 and mCDF Followed by Chemorhacidorine pay in Patients With Sign III Squamous Cell Anal  Anti-PD-1 and mCDF Followed by Chemotherapy In Patients With Sign III Squamous Cell Anal  Anti-PD-1 and mCDF Followed by Chemotherapy In Patients With Extension III Squamous Cell Anal  Anti-PD-1 Anti-Body and Follow Chemotherapy Cembined With DecidiblenChemotherapy in Patients With Extension III Squamous Cell Anal   Anti-PD-1 Anti-Body and Follow Chemotherapy Cembined With Radiotherapy in High-risk Early-Stage  Anti-PD-1 Anti-Body and Follow Chemotherapy Cembined With Chemotherapy in Patients With Node Patients Anti-Policy in Patients With Chemotherapy in Patients With Node Patients Anti-Policy International Chemotherapy in Patients With Node Patients Anti-Policy International Chem	Checkpoint inhibitor	First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)	Y		https://ClinicalTrials.gov/show/NC102041533
Checkpoint hinibitor   Anni PD-1 and body With Radiation Therapy in Patents With HERPZ-regative Metastatic Breast Cancer   Y https://clinicalTrials.gov/showNCT03434782	Checkpoint inhibitor		Υ		https://ClinicalTrials.gov/show/NCT04313660
Checkpoint Inhibitor   Ani-PD-1 and Chemotherapy for RRH Hodginin Lymphoma   Y			Υ	Y	
Checkpoint inhibitor Checkpoint inhibitor Anti-PD-1 Ambedy Alone or in Combination With Decisibine/Chemotherapy in Patients With RS-SCLC Checkpoint inhibitor Anti-PD-1 Ambedy Alone or in Combination With Decisibine/Chemotherapy in Relapsed or Refractory Mani-PD-1 Ambedy Alone or in Combination With Decisibine/Chemotherapy in Relapsed or Refractory Mani-PD-1 Ambedy Alone or in Combination With Decisibine/Chemotherapy in Relapsed or Refractory Mani-PD-1 Ambedy Alone or in Combination With Decisibine/Chemotherapy in High-risk Early-Stage PM-1 Ambedy and P-GEMOX Chemotherapy Gembined With Rediotherapy in High-risk Early-Stage PM-1 Checkpoint inhibitor Checkpoint inhibitor Anti-PD-1 in Combination With Chemotherapy as Frist-Line Treatment to Lung Cancer Checkpoint inhibitor Anti-PD-1 in Combination With Chemotherapy with or Without Bin/RAFUSP ALFA in Patients With Ambedy Chemotherapy Combined With Chemotherapy With or Without Bin/RAFUSP ALFA in Patients With Ambedy Chemotherapy Chemotherapy With Chemotherapy as Frist-Line Treatment to Lung Cancer Checkpoint inhibitor C		Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma	Υ		
Sci. Checkpoint inhibitor Ans-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancias Ans-PD-1 Antibody and P-GEMOX Chemotherapy combined With Radiotherapy in High-risk Early-Stage ENTL Checkpoint inhibitor Ans-PD-1 Antibody and P-GEMOX Chemotherapy combined With Radiotherapy in High-risk Early-Stage ENTL Checkpoint inhibitor Ans-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer Checkpoint inhibitor Ans-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer Checkpoint inhibitor Ans-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer Checkpoint inhibitor Ans-PD-1 in Combination With Chemotherapy with reviting the Stage Research of Cancer Receiving Ans-PD-1 in Combination With Chemotherapy with reviting the Stage Research of Cancer Receiving Prior Ans-PD-1 in Therapy Checkpoint inhibitor Ans-PD-1 in Combination With Chemotherapy with reviting the Stage Research of Cancer Receiving Prior Ans-PD-1 in Therapy Ans-PD-1 in Cancer Receiving Ans-PD-1 in Combination With Chemotherapy with reviting the Relapse Ovarian Cancer Treated With Checkpoint inhibitor Ans-PD-1 in Therapy Ans-PD-1 in Therapy Checkpoint inhibitor Ans-PD-1 in Therapy as First-Line Treated With PD-1 in Therapy Ans-PD-1 in Therapy as First-Line Treated With PD-1 in Therapy Ans-PD-1 in Therapy as First-Line Treated With PD-1 in Therapy Ans-PD-1 in Therapy Ans-PD-1 in Therapy as First-Line Treated With PD-1 in Therapy And Date-PD-1 in Therapy And Date-PD-1 in Therapy And Date-PD-1 i	Checkpoint inhibitor		Υ		https://ClinicalTrials.gov/show/NCT04719988
Checkpoint inhibitor Checkpoin	Checkpoint inhibitor	Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-	Υ		https://ClinicalTrials.gov/show/NCT05116007
Malignances Malignances Malignances Anii-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage PM-Anii-PD-1 Antibody and P-GEMOX Chemotherapy as First-Line Treatment to Lung Cancer  Checkpoint inhibitor Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer  Checkpoint inhibitor Anti-PD-1 in Combination With Chemotherapy was First-Line Treatment to Lung Cancer  Y https://ClinicalTrials.gov/show/NCT03432598  Checkpoint inhibitor Anti-PD-1 Therisy An	Checknoint inhibitor	Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory	Y		https://ClinicalTrials.gov/show/NCT02961101
Checkpoint inhibitor Ant-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer Y https://clinicalTrials.gov/show/NCT03425898 Checkpoint inhibitor Ant-PD-1 in Combination With Chemotherapy With or Without BINTRAFLISP ALFA in Patients With Y https://clinicalTrials.gov/show/NCT03425898 Checkpoint inhibitor Policy of Ant-PD-1 in Combination With Chemotherapy With or Without BINTRAFLISP ALFA in Patients With Y https://clinicalTrials.gov/show/NCT03425898 Checkpoint inhibitor Policy of Ant-PD-1 thorapy and the Chemotherapy With Chemotherapy in Second-line Gastric Cancer Receiving Y https://clinicalTrials.gov/show/NCT05029453 Photo-PD-1 thorapy heavaiczumab verbicache Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy Peavaiczumab verbicache Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy Beavaiczumab Chemotherapy Beavaiczumab verbicache Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy Beavaiczumab Chemotherapy in Impure System Activation in Patients With Node Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy Beavaiczumab After Chemotherapy in Impure System Activation in Patients With Node Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy in Impure System Activation in Patients With Node Phase III Study in Late Relapse Ovarian Cancer Treated With Ovarian System Activation in Patients With Node Phase III Study in Late Relapse Ovarian Cancer Available Phase Before and or With Chemocherapy in Mills Chemotherapy in Patients With Node Phase III Study in Late Relapse Ovarian Cancer Available Phase III Study in Late Relapse Ovarian Cancer Available Phase III Study in Late Relapse Ovarian Cancer Available Phase III Study in Late Relapse Ovarian Cancer Available Phase III Study in Late Relapse Ovarian Cancer Available Phase III Study in Late Relapse Ovarian Cancer III S					
Checkpoint inhibitor Metastate Advanced Stage Ovarian Cancer Metastate Cancer Receiving Prior Anta-Pto-Prior Prior	1	ENKTL			
Apalish Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving					
Checkpoint inhibitor Checkpoin	Checkpoint inhibitor				
Checkpoint inhibitor Checkpoin	Checkpoint inhibitor	Prior Anti-PD-1 Therapy	Y		https://ClinicalTrials.gov/show/NCT05029453
Checkpoint inhibitor   Azeolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy   Y   https://clinicalTrials.gov/show/NCT0335928	Checkpoint inhibitor		Υ		https://ClinicalTrials.gov/show/NCT02891824
Checkpoint inhibitor Checkpoin		Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy			
Checkpoint inhibitor Chemotherapy Avelumab With Neuroendocrine Carcinomas (NEC G3) Progressive After Checkpoint inhibitor Checkpoint in		Positive Stage IB2, II, IIIB, or IVA Cervical Cancer			, ,
Checkpoint inhibitor Checkpoin					
Checkpoint inhibitor Checkpoin		Chemotherapy		· · · · · · · · · · · · · · · · · · ·	
Mulant Glioblastoma  Checkpoint inhibitor  Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)  Bempegaldesielwin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma  Checkpoint inhibitor  Checkpoint inhibitor  Biomarker Analysis in High PD-11 Expressing NSCLC Patients Treatment in Adults With Inoperable, Locality Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma  Checkpoint inhibitor  Checkpoint inhibitor  Checkpoint inhibitor  Checkpoint inhibitor  Checkpoint inhibitor  Cancer (KEYNOTE-782, MK-3475-782)  Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)  Checkpoint inhibitor  Check		Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH)	Y		
Checkpoint inhibitor   Sempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma   Y   https://ClinicalTrials.gov/show/NCT04936841		Mutant Glioblastoma		i	
Squamous Cell Carcinoma  Checkpoint Inhibitor  Squamous Cell Carcinoma  BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma  Checkpoint inhibitor  Silomarker Analysis in High PD-1, Expressing NSCL C Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platianum Based Chemotherapy  Checkpoint inhibitor  Silomarker Analysis in High PD-1, Expressing NSCL C Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platianum Based Chemotherapy  Checkpoint inhibitor  Silomarker Analysis in High PD-1, Expressing NSCL C Patients Treated With PD-1/PD-L1 Based Therapy With Development of Public Patients of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)  Checkpoint inhibitor  Cancer (KEYNOTE-782, MK-3475-782)  BlaAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1-A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia  Checkpoint inhibitor  Carcinomas  Checkpoint inhibitor  Carrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas  Checkpoint inhibitor  Carmelizumab Combined With Induction Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma  Y https://ClinicalTrials.gov/show/NCT04635956	Checkpoint inhibitor	(BRAVA)	Y		https://ClinicalTrials.gov/show/NCT04943627
Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma  Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)  Checkpoint inhibitor  Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)  Checkpoint inhibitor  Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)  Checkpoint inhibitor  Cancer (KEYNOTE-782, MK-3475-782)  BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontine Therapy in Patients With Acute Myeloid Leukemia  Checkpoint inhibitor  Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission  Checkpoint inhibitor  Camerizumab Combined With Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinomaa  Camerizumab Combined With Induction Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinomaa	Checkpoint inhibitor			Υ	https://ClinicalTrials.gov/show/NCT04936841
Checkpoint inhibitor   Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy   Y   https://ClinicalTrials.gov/show/NCT04676386   With or Without the Addition of Platnum Based Chemotherapy in Non-Small Cell Lung   Siomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung   Y   https://ClinicalTrials.gov/show/NCT03664024   https://ClinicalTrials.gov/show/NCT03664024   Biomarker of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung   Y   https://ClinicalTrials.gov/show/NCT03664024   https://ClinicalTrials.gov/show/NCT03664024   Biomarker of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung   Y   https://ClinicalTrials.gov/show/NCT03664024   https://ClinicalTrials.gov/show/NCT03664024   https://ClinicalTrials.gov/show/NCT03664024   https://ClinicalTrials.gov/show/NCT04214249   https://ClinicalTrials.gov/sho	Checkpoint inhibitor		Υ		https://ClinicalTrials.gov/show/NCT03469557
With or Without the Addition of Hahnum Based Chemotherapy in Non-Small Cell Lung Checkpoint inhibitor Cancer (KEYNOTE-782, MK-3475-782)  Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)  Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)  Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)  Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)  BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1-A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia  Checkpoint inhibitor Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission Checkpoint inhibitor Carcinomas  Checkpoint inhibitor Carmelizumab Combined With Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma	Checkpoint inhibitor	Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy	Y		https://ClinicalTrials.gov/show/NCT04676386
Cancer (KEYNOTE-782, MK-3475-782)  Checkpoint inhibitor  Cancer (KEYNOTE-782, MK-3475-782)  Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)  RLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1-A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia  Checkpoint inhibitor  Checkpoint inhibitor  Checkpoint inhibitor  Checkpoint inhibitor  Carcinomas  Checkpoint inhibitor  Carrelizumab Combined With Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma  Thess//ClinicalTrials.gov/show/NCT01096602	·				
Cancer (KEYNDTE-782, MK-347-782)  BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1-A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia  Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission  Checkpoint inhibitor  Carrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Checkpoint inhibitor  Carrelizumab Combined With Induction Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinomas  These Mitter of Treatment of Locally Advanced Nasopharyngeal Carcinoma	Checkpoint inhibitor	Cancer (KEYNOTE-782, MK-3475-782)			mups://ClinicalTrials.gov/show/NC103664024
Checkpoint inhibitor Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Checkpoint inhibitor Checkpoint inhibitor Camrelizumab Combined With Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinomas  Checkpoint inhibitor Camrelizumab Combined With Induction Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma	Checkpoint inhibitor		Y		https://ClinicalTrials.gov/show/NCT03664024
Cembination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia  Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Carcinomas  Checkpoint inhibitor Carrelizumab Combined With Induction Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma					
Checkpoint inhibitor Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission  Checkpoint inhibitor Carrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Y https://ClinicalTrials.gov/show/NCT04635956  Checkpoint inhibitor Carrelizumab Combined With Induction Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinomas  Checkpoint inhibitor Treatment of Locally Advanced Nasopharyngeal Carcinoma	Checkpoint inhibitor	Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid	Y		https://ClinicalTrials.gov/show/NCT04214249
Remission  Cameriizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas  Checkpoint inhibitor  Checkpoint inhibito	Chackpoint in hilbits	Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced	~		https://ClinicalTrials.gov/show/NOT04006600
Carcinomas Checkpoint inhibitor Carrinomas Checkpoint inhibitor Treatment of Locally Advanced Nasopharyngeal Carcinoma		Remission			
Treatment of Locally Advanced Nasopharyngeal Carcinoma  Treatment of Locally Advanced Nasopharyngeal Carcinoma	Checkpoint inhibitor	Carcinomas	Y		https://ClinicalTrials.gov/show/NCT04635956
	Checkpoint inhibitor		Y		https://ClinicalTrials.gov/show/NCT05097209
	Chackpoint inhibitor		Υ		https://ClinicalTrials.gov/show/NCT04530227

Checkpoint inhibitor	Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy	Υ		https://ClinicalTrials.gov/show/NCT04646009
Checkpoint inhibitor	Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer	Y	Y	https://ClinicalTrials.gov/show/NCT03383094
Checkpoint inhibitor	Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients	Υ		https://ClinicalTrials.gov/show/NCT05374252
Checkpoint inhibitor	Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial	Υ		https://ClinicalTrials.gov/show/NCT0534049
Checkpoint inhibitor	Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC	Y		https://ClinicalTrials.gov/show/NCT04189094
Checkpoint inhibitor	Chemotherapy Combined With Apatinib and PD-1 Antibody	Y		https://ClinicalTrials.gov/show/NCT05025033
Checkpoint inhibitor Checkpoint inhibitor	Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC  Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC	Y Y		https://ClinicalTrials.gov/show/NCT04324129 https://ClinicalTrials.gov/show/NCT05267366
Checkpoint inhibitor	Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts:	Y		https://ClinicalTrials.gov/show/NCT0432259
эпоскронк ниныког	the POSEIDON Trial  Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De			Inapoline in indicate in indic
Checkpoint inhibitor	Novo Metastatic Nasopharyngeal Carcinoma	Υ		https://ClinicalTrials.gov/show/NCT04398056
Checkpoint inhibitor	Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors	Y		https://ClinicalTrials.gov/show/NCT03656094
Checkpoint inhibitor	Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm	Υ		https://ClinicalTrials.gov/show/NCT05113355
Checkpoint inhibitor	Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally	Y		https://ClinicalTrials.gov/show/NCT04922450
	Advanced Head and Neck Squamous Cell Carcinoma  Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced			
Checkpoint inhibitor	Thymic Epithelial Tumor	Y		https://ClinicalTrials.gov/show/NCT04667793
Checkpoint inhibitor	Clinical Study of PD-1 Antibody (BGB-A317) Plus Chemotherapy (Cisplatin and Etoposide) for Limited Stage Small Cell Lung Cancer	Υ		https://ClinicalTrials.gov/show/NCT04542369
>bli-+ i-bibit	Clinical Study of PD-L1 Antibody (TQB2450) Plus Chemotherapy (Cisplatin and Etoposide) for Previously	Y		
Checkpoint inhibitor	Untreated Small Cell Lung Cancer	Y		https://ClinicalTrials.gov/show/NCT04539977
Checkpoint inhibitor	Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric	Υ		https://ClinicalTrials.gov/show/NCT05149807
Checkpoint inhibitor	Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-	Υ		https://ClinicalTrials.gov/show/NCT03281954
	Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo			
Checkpoint inhibitor	Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma	Υ		https://ClinicalTrials.gov/show/NCT0441373
Checkpoint inhibitor	Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer	Y		https://ClinicalTrials.gov/show/NCT0397727
Checkpoint inhibitor Checkpoint inhibitor	Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer  Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC	Y Y		https://ClinicalTrials.gov/show/NCT0398305 https://ClinicalTrials.gov/show/NCT0367126
Checkpoint inhibitor	Combination of Chemotherapy Plus R1 and SHR-1210 to Treat Patients With ESCC  Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer	ı	Y	https://ClinicalTrials.gov/show/NCT0367126
heckpoint inhibitor	Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With		Y	https://ClinicalTrials.gov/show/NCT0318731
	Esophageal Cancer  Combination Radiation and RD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)		Y	https://ClinicalTrials.gov/show/NCT0296280
heckpoint inhibitor	Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)  Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in		Y	
Checkpoint inhibitor	Patients With Lung Cancer	Y		https://ClinicalTrials.gov/show/NCT0340961
heckpoint inhibitor	Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC		Y	https://ClinicalTrials.gov/show/NCT0364482
N	Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating	Y		http://clinicalTriala.aa./abaa./AlcT0460602
Checkpoint inhibitor	Limited-Stage Small Cell Lung Cancer Patients	Y		https://ClinicalTrials.gov/show/NCT0469693
heckpoint inhibitor	Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy	Υ		https://ClinicalTrials.gov/show/NCT0454127
Checkpoint inhibitor	Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody	Y		https://ClinicalTrials.gov/show/NCT0395159
Checkpoint inhibitor	(JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma  Combining RT With Toripalimab and Chemotherapy in Metastatic Nasopharyngeal Carcinoma	Y		https://ClinicalTrials.gov/show/NCT0538592
Checkpoint inhibitor	Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma	Y		https://ClinicalTrials.gov/show/NCT0451721
Checkpoint inhibitor	Comparing the New Anti-cancer Drug Eribulin With or Without Chemotherapy Against the Usual	Υ		https://ClinicalTrials.gov/show/NCT0457922
	Chemotherapy Alone in Metastatic Urothelial Cancer  Concurrent and Adjuvant PD-1 Blockade Combined With Induction Chemotherapy Plus Radiotherapy in			
Checkpoint inhibitor	Nasopharyngeal Carcinoma	Y		https://ClinicalTrials.gov/show/NCT0398435
heckpoint inhibitor	Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma	Υ		https://ClinicalTrials.gov/show/NCT0445382
	Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III	.,	.,	
		Y	Y	https://ClinicalTrials.gov/show/NCT0388419
Sheckpoint minibilor	NSCLC			
	NSCLC CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for		Y	https://ClinicalTrials.gov/show/NCT0373243
Checkpoint inhibitor	NSCLC	V	Υ	
Checkpoint inhibitor	NSCLC CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab	Y	Y	
Checkpoint inhibitor	NSCLC CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With	Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 IPD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial			https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	NSCLC CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients CTLA-4 IPD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 NO-2 Wb) of the Bladder		Y	https://ClinicalTrials.gov/show/NCT0373243 https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 IPD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 NO-2 MIO) of the Bladder  Durvalumab In Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-			https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-18 Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma	Y		https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116 https://ClinicalTrials.gov/show/NCT0430177
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	NSCLC CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Distamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 No-2 Mio) of the Bladder Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma	Y Y Y		https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116 https://ClinicalTrials.gov/show/NCT0430177
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-18 Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma	Y		https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116 https://ClinicalTrials.gov/show/NCT0430177
Checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 IPD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 No-2 Mio) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Changiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic	Y Y Y		https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177
Checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 PPD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 Ml) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma	Y Y Y		https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177
Checkpoint inhibitor	NSCLC CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients CTLA-4 IPD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 No-2 Ml) of the Bladder Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization or Patients With Intrahepatic Chalangiocarcinoma Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization or Patients With Intrahepatic Chalangiocarcinoma Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA-Study) Durvalumab Vits CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma Durvalumab vis Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimerfinib Following SBRT in Patients With Early Stage	Y Y Y		https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0330747
Checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 NO-2 Mio) of the Bladder  Durvalumab In Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With CBF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA-Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimerinib Following SBRT in Patients With Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimerinib Following SBRT in Patients With Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimerinib Following SBRT in Patients With Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimerinib Following SBRT in Patients With Early Stage	Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0390747
Checkpoint inhibitor	NSCLC CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients CTLA-4 IPD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 No-2 Ml) of the Bladder Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization or Patients With Intrahepatic Chalangiocarcinoma Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization or Patients With Intrahepatic Chalangiocarcinoma Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA-Study) Durvalumab Vits CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma Durvalumab vis Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimerfinib Following SBRT in Patients With Early Stage	Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0383315
checkpoint inhibitor checkpoint inhibitor checkpoint inhibitor checkpoint inhibitor checkpoint inhibitor checkpoint inhibitor checkpoint inhibitor checkpoint inhibitor checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distannab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 NO-2 Mio) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarrinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarrinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA-Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Anti-Oring an EGFR Mutation  Durvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma  Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer	Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0337665 https://ClinicalTrials.gov/show/NCT038315
checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 IPD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial  Cancer (T2-4 N0-2 M0) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarrinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarrinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarrinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA-Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab via Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCL C) Patients / Visional Combined Stage Unresected NSCLC Harboring an EGFR Mutation  DurValumab with chemotherapy as First Line teal/Iment in Advanced Pleural Mesothelioma  Durvalumab An Anti-PDLI Antibody, and Chemoradiation	Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0383315 https://ClinicalTrials.gov/show/NCT0433475 https://ClinicalTrials.gov/show/NCT0433475
checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLG-4 iPD-L1 Blockade Following Transarderial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 No-2 Mio) of the Bladder  Cancer (T2-4 No-2 Mio) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA-Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation  DurValumab With chemotherapy as First Line tealment in Advanced Pleural Mesothelioma  Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer  Durvalumab (MEDI4736) After chemoRadio Therapy (DART) for NSCLC-a Translational and Biomarker Study	Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT03307665 https://ClinicalTrials.gov/show/NCT033315 https://ClinicalTrials.gov/show/NCT0433475 https://ClinicalTrials.gov/show/NCT0433475
heckpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 IPD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial  Cancer (T2-4 N0-2 M0) of the Bladder  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial  Cancer (T2-4 N0-2 M0) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-  Embolization for Patients With Intrahepatic Cholangiocarrinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-  Embolization for Patients With Intrahepatic Cholangiocarrinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (  DURVA+ Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Cell Lung Cancer (NSCL C) Patients / Giberiator Solidor Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCL C) Patients / Giberiator Solidor	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511348 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0300747 https://ClinicalTrials.gov/show/NCT0330747 https://ClinicalTrials.gov/show/NCT03307468 https://ClinicalTrials.gov/show/NCT033318 https://ClinicalTrials.gov/show/NCT0333478 https://ClinicalTrials.gov/show/NCT0439478 https://ClinicalTrials.gov/show/NCT0439478 https://ClinicalTrials.gov/show/NCT0439256
heckpoint inhibitor heckpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distannab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 No-2 Mio) of the Bladder  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 No-2 Mio) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVAr Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Amonth and EGFR Mutation  Durvalumab, an Anti-SCLC Amonth and EGFR Mutation  Durvalumab, an Anti-DUI Antibody, and Tremelimumab, an Anti-CTLAA Antibody, and Chemoradiation Before Surgery for Esophageal Cancer  Durvalumab (MEDI4736) After chemoRadio Therapy (DART) for NSCLC-a Translational and Biomarker Study  Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for NSCLC	Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0397665 https://ClinicalTrials.gov/show/NCT0383315 https://ClinicalTrials.gov/show/NCT0433475 https://ClinicalTrials.gov/show/NCT04392506 https://ClinicalTrials.gov/show/NCT04392506 https://ClinicalTrials.gov/show/NCT04392506 https://ClinicalTrials.gov/show/NCT04392506 https://ClinicalTrials.gov/show/NCT0458646 https://ClinicalTrials.gov/show/NCT0458646 https://ClinicalTrials.gov/show/NCT0458646 https://ClinicalTrials.gov/show/NCT0458646 https://ClinicalTrials.gov/show/NCT0458646
heckpoint inhibitor heckpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 No-2 Mol) of the Bladder  Durvalumab In Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVAr-Study)  Durvalumab Plus CV301 With Malintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab ve Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unre	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0397665 https://ClinicalTrials.gov/show/NCT0337665 https://ClinicalTrials.gov/show/NCT033476 https://ClinicalTrials.gov/show/NCT043476 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0458646 https://ClinicalTrials.gov/show/NCT0458646 https://ClinicalTrials.gov/show/NCT0370160 https://ClinicalTrials.gov/show/NCT0370160 https://ClinicalTrials.gov/show/NCT0368460 https://ClinicalTrials.gov/show/NCT0370160
theckpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 No-2 Mio) of the Bladder  Durvalumab In Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Amonth of the Patients of Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Amonth of the Patients of Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Amonth of the Patients of Cancer	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0397655 https://ClinicalTrials.gov/show/NCT0337655 https://ClinicalTrials.gov/show/NCT0433475 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0488466 https://ClinicalTrials.gov/show/NCT04586466 https://ClinicalTrials.gov/show/NCT04586466 https://ClinicalTrials.gov/show/NCT0370160 https://ClinicalTrials.gov/show/NCT0370160
checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 No-2 Mol) of the Bladder  Durvalumab In Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVAr-Study)  Durvalumab Plus CV301 With Malintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab ve Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unre	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0289116 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT033315 https://ClinicalTrials.gov/show/NCT033475 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0458646 https://ClinicalTrials.gov/show/NCT0370160 https://ClinicalTrials.gov/show/NCT0368340 https://ClinicalTrials.gov/show/NCT0368340 https://ClinicalTrials.gov/show/NCT0370160 https://ClinicalTrials.gov/show/NCT0368340 https://ClinicalTrials.gov/show/NCT0370160
Checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Cancer  Clark (T2-4 N0-2 M0) of the Bladder  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial  Cancer (T2-4 N0-2 M0) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCL C) Patients / Vistage Unresected NSCL C Harboring an EGFR Mutation  Durvalumab With chemotherapy as First Line teckment in Advanced Pleural Mesothelioma  Durvalumab With chemotherapy as First Line teckment in Advanced Pleural Mesothelioma  Durvalumab With Chemotherapy as First Line teckment in Advanced Pleural Mesothelioma  Durvalumab With Chemotherapy as First Line teckment in Advanced Pleural Mesothelioma  Durvalumab With Chemotherapy as First Line teckment in Advanced Pleural Mesothelioma  Durvalumab With Chemotherapy on PD-L1 in NSCLC  Effect of Chemotherapy on PD-L1 in NSCLC  Effect of Chemotherapy on TMB in NSCLC  Effect of Chemotherapy on PD-L1 in NSCL	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0337665 https://ClinicalTrials.gov/show/NCT033315 https://ClinicalTrials.gov/show/NCT0433475 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0458646 https://ClinicalTrials.gov/show/NCT0370160 https://ClinicalTrials.gov/show/NCT0517432 https://ClinicalTrials.gov/show/NCT0517432
Checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distannab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 No-2 Mo) of the Bladder  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 No-2 Mo) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA-Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimerinib Following SBRT in Patients With Early Stage Unresected Not-Small Cell Lung Cancer (NSCLC) Patients / Osimerinib Following SBRT in Patients With Early Stage Unresected Not-Small Cell Lung Cancer (NSCLC) Patients / Osimerinib Following SBRT in Patients With Early Stage Unresected Not-Small Cell Lung Cancer (NSCLC) Patients / Osimerinib Following SBRT in Patients With Early Stage Unresected Not-Small Cell Lung Cancer (NSCLC) Patients / Osimerinib Following SBRT in Patients With Early Stage Unresected Not-Small Cell Lung Cancer (NSCLC) Patients / Osimerinib Following SBRT in Patients With Early Stage Unresected Not-Small Cell Lung Cancer (NSCLC) Patients / Osimerinib Following SBRT in Patients With Early Stage Unresected Not-Small Patients of Oper	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0337665 https://ClinicalTrials.gov/show/NCT033315 https://ClinicalTrials.gov/show/NCT0433475 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0458646 https://ClinicalTrials.gov/show/NCT0370160 https://ClinicalTrials.gov/show/NCT0517432 https://ClinicalTrials.gov/show/NCT0517432
Checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 IPD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distannab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 NO-2 Mio) of the Bladder  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 NO-2 Mio) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA-Study)  Durvalumab In Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA-Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab ve Placebo With Stereotactic Body Radiation Therapy in Berry Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patents / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation  Durvalumab with Chemotherapy as First Line treAtment in Advanced Pleural Mesothelioma  Durvalumab With Chemotherapy as First Line treAtment in Advanced Pleural Mesothelioma  Durvalumab (MEDI4736) After chemodatio Therapy (DART) for NSCLC - Translational and Biomarker Study  Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for NSCLC  Effect of Chemotherapy on PD-L1 in NSCLC  Effectiveness of Neoadjuvant Chemotherapy Combined With Platinum-Based Chemotherapy and Bevaczumab in Patients With Advanced Non-Squamous NSCLC  Effect of Chemotherapy on TMB in NSCLC  Effectiveness of Neoadjuvant Chemotherapy Combined With	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0397645 https://ClinicalTrials.gov/show/NCT0337665 https://ClinicalTrials.gov/show/NCT0433475 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0458646 https://ClinicalTrials.gov/show/NCT0370166 https://ClinicalTrials.gov/show/NCT0370166 https://ClinicalTrials.gov/show/NCT0517432 https://ClinicalTrials.gov/show/NCT0517432 https://ClinicalTrials.gov/show/NCT0517432
Checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 NO-2 Mil) of the Bladder  Durvalumab In Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA-Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab ve Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients of Science Surgery for Esophageal Cancer  Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-PDL Osmbination and Biomarker Study  Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy on TMB in NSCLC  Effect of Chemotherapy on TMB in NSCLC	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT039765 https://ClinicalTrials.gov/show/NCT0337655 https://ClinicalTrials.gov/show/NCT0433475 https://ClinicalTrials.gov/show/NCT0458646 https://ClinicalTrials.gov/show/NCT0458646 https://ClinicalTrials.gov/show/NCT0370160 https://ClinicalTrials.gov/show/NCT0370160 https://ClinicalTrials.gov/show/NCT0370160 https://ClinicalTrials.gov/show/NCT0517432 https://ClinicalTrials.gov/show/NCT0517432
Checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Cancer  Clark (T2-4 ND-2 MD) of the Bladder  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial  Cancer (T2-4 ND-2 MD) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA-Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab va Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCL C) Patients / Visit Pa	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0311345 https://ClinicalTrials.gov/show/NCT039116 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0337665 https://ClinicalTrials.gov/show/NCT033315 https://ClinicalTrials.gov/show/NCT0333475 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0391638446 https://ClinicalTrials.gov/show/NCT0391638446 https://ClinicalTrials.gov/show/NCT0391238 https://ClinicalTrials.gov/show/NCT0391238
Checkpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 NO-2 Mil) of the Bladder  Durvalumab In Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA-Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab ve Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients of Science Surgery for Esophageal Cancer  Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-PDL Osmbination and Biomarker Study  Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy on TMB in NSCLC  Effect of Chemotherapy on TMB in NSCLC	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345
checkpoint inhibitor	NSCLC  CTGuided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distannab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 No-2 Mio) of the Bladder  Durvalumab In Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarrainoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarrainoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVAr Study)  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab Sv Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) And Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer  Durvalumab, an Anti-PD1 Inhibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer  Durvalumab (MEDI4736) After chemoRadio Therapy(DART) for NSCLC-a Translational and Biomarker Study  Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy and TMB in NSCLC  Effect of Chemotherapy on TMB in NSCLC  Effect of Chemotherapy on TMB in NSCLC  Eff	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0311345 https://ClinicalTrials.gov/show/NCT039116 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0337665 https://ClinicalTrials.gov/show/NCT033315 https://ClinicalTrials.gov/show/NCT0333475 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0439250 https://ClinicalTrials.gov/show/NCT0391638446 https://ClinicalTrials.gov/show/NCT0391638446 https://ClinicalTrials.gov/show/NCT0391238 https://ClinicalTrials.gov/show/NCT0391238
heckpoint inhibitor	NSCLC  CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients  CTLA-4 IPD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab  Distannab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 NO-2 Mio) of the Bladder  Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 NO-2 Mio) of the Bladder  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)  Durvalumab in Lower Study (Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma  Durvalumab ve Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimerinib Following SBRT1 in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation  Durvalumab with chemotherapy as First Line treAlment in Advanced Pleural Mesothelioma  Durvalumab An Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLAA Antibody, and Chemoradiation Before Surgery for Esophageal Cancer  Durvalumab (MED14736) After chemoRadio Therapy(DART) for NSCLC-a Translational and Biomarker Study  Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy and Bromehoscopy-assisted in Combination With Platinum-Based Chemothe	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0363814 https://ClinicalTrials.gov/show/NCT0511345 https://ClinicalTrials.gov/show/NCT039116 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0430177 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT0390747 https://ClinicalTrials.gov/show/NCT03307665 https://ClinicalTrials.gov/show/NCT033315 https://ClinicalTrials.gov/show/NCT033475 https://ClinicalTrials.gov/show/NCT0496206 https://ClinicalTrials.gov/show/NCT0496206 https://ClinicalTrials.gov/show/NCT0391240

Checkpoint inhibitor	Efficacy and Safely of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-0000-316/LEAP-008)	Υ		https://ClinicalTrials.gov/show/NCT03976375
Checkpoint inhibitor	Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE- B99)	Υ		https://ClinicalTrials.gov/show/NCT04924101
Checkpoint inhibitor	Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer	Y		https://ClinicalTrials.gov/show/NCT04367025
Checkpoint inhibitor	Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A	Υ		https://ClinicalTrials.gov/show/NCT04517526
Checkpoint inhibitor	Multicenter, Prospective, Phase II Clinical Study  Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy  Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer	Υ		https://ClinicalTrials.gov/show/NCT03635567
Checkpoint inhibitor	(MK-3475-826/KEYNOTE-826)  Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti-Programmed Death-ligand 1 (PD-IL)t1) Therapy and Chemotherapy	Y		https://ClinicalTrials.gov/show/NCT04655976
Checkpoint inhibitor	Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma	Υ		https://ClinicalTrials.gov/show/NCT04225364
Checkpoint inhibitor	Efficacy of PD-1 Blockade Plus Platinum-based Chemotherapy in Patients With EGFR Sensitive Mutated NSCLC	Υ		https://ClinicalTrials.gov/show/NCT05284539
Checkpoint inhibitor	Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer  Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II	Y		https://ClinicalTrials.gov/show/NCT04250948
Checkpoint inhibitor	Trial.  Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy	Y		https://ClinicalTrials.gov/show/NCT05397769
Checkpoint inhibitor	Immunotherapy in Patients With Solid Tumors of the Chest.  First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-	Υ		https://ClinicalTrials.gov/show/NCT05044728
Checkpoint inhibitor	590/KEYNOTE-590)	Y		https://ClinicalTrials.gov/show/NCT03189719
Checkpoint inhibitor	First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study	Υ		https://ClinicalTrials.gov/show/NCT03881111
Checkpoint inhibitor	Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy	Υ		https://ClinicalTrials.gov/show/NCT04978012
Checkpoint inhibitor	GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in	Υ		https://ClinicalTrials.gov/show/NCT05023109
Checkpoint inhibitor	Advanced BTC	Y		https://ClinicalTrials.gov/show/NCT05019677
Checkpoint inhibitor	GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab	Y		https://ClinicalTrials.gov/show/NCT04652076
Checkpoint inhibitor	Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric	Y		https://ClinicalTrials.gov/show/NCT04945720
Checkpoint inhibitor	Cancer	Y		https://ClinicalTrials.gov/show/NCT05246982
Checkpoint inhibitor	HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors	Y		https://ClinicalTrials.gov/show/NCT05173142
Checkpoint inhibitor	HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer	Υ		https://ClinicalTrials.gov/show/NCT04750083
Checkpoint inhibitor	Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer		Υ	https://ClinicalTrials.gov/show/NCT02311361
Checkpoint inhibitor	Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma	Υ		https://ClinicalTrials.gov/show/NCT04908566
Checkpoint inhibitor	Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy	Υ		https://ClinicalTrials.gov/show/NCT04188860
Checkpoint inhibitor	Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial	Υ		https://ClinicalTrials.gov/show/NCT05290935
Checkpoint inhibitor	Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer  Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage	Y		https://ClinicalTrials.gov/show/NCT03249142
Checkpoint inhibitor	SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy  INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung			https://ClinicalTrials.gov/show/NCT03911219
Checkpoint inhibitor	Cancer (POD1UM-301)	Y	Y	https://ClinicalTrials.gov/show/NCT04203511
Checkpoint inhibitor	INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable			https://ClinicalTrials.gov/show/NCT03920839
Checkpoint inhibitor		Y		Intips://Clinicalinals.gov/snow/NC104995120
Checkpoint inhibitor	Laryngeal/Hypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic	Y	٧	https://ClinicalTrials.gov/show/NCT04995120
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Laryngeal/Hypopharyngeal Carcinoma	Y	Y	https://ClinicalTrials.gov/show/NCT03354962
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Laryngeal/Hypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC			https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Laryngeal/Hypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patents Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC	Y	Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) (ID102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC (ID102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC (pilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma (KEYMAKER-U101 Substudy 1: Effacey and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na@v Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01AKEYMAKER-U01A) (KEYMAKER-U101 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab	Y Y		https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Laryngeal/Hypopharyngeal Carcinoma induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) (IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC 10102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma (KEYMAKER-U101 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na6ve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01AKEYMAKER-U01A) (KKYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)  Lenvatinia (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard	Y		https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) (10102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [pillimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma KEYMAKER-101 Substudy 1 - Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na tave Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01AKEYMAKER-U01A) KEYMAKER-101 Unthrella Master Study; Suties of Investigational Agents with Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) Lenvalthia (E7080MK-7902) in Combination with Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With RecurrentMetastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-	Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151
Checkpoint inhibitor	Laryngeal/Hypopharyngeal Carcinoma induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) [I0102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [I0102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [I0102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [I0102 With Pembrolizumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma KEYMAKER-U101 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na@ve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01AKEYMAKER-U101)  KEYMAKER-U101 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)  Lenvatinitic (E7080MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinit Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902- 1099E7080-G000-228LEAP-009)  Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III  NSCLC After Chemoradiation and Anti-PD-L1 Therapy	Y	Y	https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04165798
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC plitimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Orophanyngeal Squamous Cell Carcinoma KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na dive Participants With Advanced Non-small Cell Lung Caner (NSCLC) (MK-375-01 AKEYMAKER-U014) KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Caner (NSCLC) (MK-3475-U10*KYMAKER-U014) Lenvatinib (E7080MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Invanionative applications and Anti-PD-L1 Therapy Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy Local Consolidative Therapy and Durvalumab for Oligoprogressive and Avelumab With or Without Cellular Adoptive Immunotherapy (MK-3405) With Metastatic Merkel Cell Carcinoma	Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BCOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC plilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na dive Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-375-01AKEYMAKER-U014) KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U014 NEWAKER-U014) Lenvatinib (67080MK-7902) in Combination With Pembrolizumab (MK-3475) Vis. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009)/E7080-0000-228/LEAP-009) NSCLC After Chemoradiation and Anti-PD-L1 Therapy Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Colid Tumors	Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03454962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04892953 https://ClinicalTrials.gov/show/NCT0488829 https://ClinicalTrials.gov/show/NCT02584829 https://ClinicalTrials.gov/show/NCT04866888
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC Iplimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-ata®ve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01AKEYMAKER-U014) KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475-01AKEYMAKER-U015) Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (PULS Chemotherapy and Lenvatinib Monotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009) Local Consolidative Therapy and Durivalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PO-1 Threating Patients With Metastatic Solid LYT-200 Alone and in Combination With Chemotherapy or Art-PO-1 in Patients With Metastatic Solid	Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04892953 https://ClinicalTrials.gov/show/NCT02584829 https://ClinicalTrials.gov/show/NCT04666688 https://ClinicalTrials.gov/show/NCT04666688
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC plilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na dive Participants With Advanced Non-small Cell Lung Caner (NSCLC) (MK-375-01AKEYMAKER-U01) KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Caner (MSCLC) (MK-3475-U01) Lenvalinib (E7080MK-7902) in Combination With Pembrolizumab (MK-3475) Vis. Standard Chemotherapy and Lenvalinib Monotherapy in Participants With Recurrent/Whetastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902) 009/E7080-0000-220ALEAP-009) Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L-1 Therapy Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors MPDL32200 A With Chemoradiation for Lung Cancer Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.	Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04892953 https://ClinicalTrials.gov/show/NCT04866688 https://ClinicalTrials.gov/show/NCT04666688 https://ClinicalTrials.gov/show/NCT04666688 https://ClinicalTrials.gov/show/NCT02525757 https://ClinicalTrials.gov/show/NCT04753879
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic NSCLC ICI012 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC ICI012 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC Ici012 With Pembrolizumab, Nivlourmab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na & Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (IMK-3475-01AKEYMAKER-U014) KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (IMK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (IMK-3475-U01 KYMAKER-U014) Lenvatinib (£7080/MK-7902) in Combination With Pembrolizumab (IMK-3475) Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902- 009/E7080-G000-228/LEAP-009) Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy Local Consolidation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors MPDL32	Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT033562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT044892953 https://ClinicalTrials.gov/show/NCT02584829 https://ClinicalTrials.gov/show/NCT02584829 https://ClinicalTrials.gov/show/NCT0466688 https://ClinicalTrials.gov/show/NCT0466688
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na tigve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-375-01AKEYMAKER-U014) KEYMAKER-U01 Umbrella Master Study: Sudies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab (USC Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) Lenvatinit (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) s. Standard Chemotherapy and Lenvatinith Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-09) Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Metad and Neck Squamous Cell Carcinoma LTY-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors MPDL2380A With Chemotherapy in Treating Patients With Metastatic Pancreatic Ductal Cancer. MBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Pancre	Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT033562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04892953 https://ClinicalTrials.gov/show/NCT04566688 https://ClinicalTrials.gov/show/NCT04666688 https://ClinicalTrials.gov/show/NCT04666688 https://ClinicalTrials.gov/show/NCT02525757 https://ClinicalTrials.gov/show/NCT0452587879
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IDIImmab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na 8 Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01AKEYMAKER-U014) KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab Non-small Cell Lung Cancer (NSCLC) (MK-3475-01AKEYMAKER-U014) Lenvatinic (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009) Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Amit-PD-L1 Therapy Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma LTV-7200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors MUIt-agent Low Dose Chemotherapy GAX-Cl Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer Multi-agent Low Dose Chemotherapy GAX-Cl Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer Multi-agent Low Dose Chemotherapy CaX-Cl Followed by Olaparib and Pembro in Metasta	Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT033562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04482953 https://ClinicalTrials.gov/show/NCT04892953 https://ClinicalTrials.gov/show/NCT04566688 https://ClinicalTrials.gov/show/NCT04563879 https://ClinicalTrials.gov/show/NCT04508051 https://ClinicalTrials.gov/show/NCT04508051 https://ClinicalTrials.gov/show/NCT05080651 https://ClinicalTrials.gov/show/NCT05036632
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BCOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [10102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC plilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na®ve Participants With Advanced Non-small Cell Lung Caner (NSCLC) (MK-375-01AKEYMAKER-U01) KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Caner (NSCLC) (MK-3475-U104 NEWAKER-U01) Lenvalinib (E7080MK-7902) in Combination With Pembrolizumab (MK-3475) With Advanced Non-small Cell Lung Caner (MSCLC) (MK-3475-U104 NEWAKER-U01) Lenvalinib (E7080MK-7902) in Combination With Pembrolizumab (MK-3475) Standard Chemotherapy and Lenvalinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-000-228/LEAP-009) Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L-1 Therapy Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors MPD12320A With Chemoradiation for Lung Cancer Mutti-agent Low Dose Chemotherapy Greporative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Loc	Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04482953 https://ClinicalTrials.gov/show/NCT04584829 https://ClinicalTrials.gov/show/NCT04568688 https://ClinicalTrials.gov/show/NCT04553879 https://ClinicalTrials.gov/show/NCT045388051 https://ClinicalTrials.gov/show/NCT0456285557 https://ClinicalTrials.gov/show/NCT045638051 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [Io102 With Pembrolizumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma  KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na (3ve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01AKEMAKER-U014)  KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab (USC Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)  Lenvatinit (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) s. Standard Chemotherapy and Lenvatatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-09)  Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemotradiation and Anti-PD-1.1 Therapy  Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma  LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors  MPDL3280A With Chemotradiation for Lung Cancer  MBTKR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Pancreatic Ductal Cancer.  NBTKR3, Radiation Therapy, an	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04492953 https://ClinicalTrials.gov/show/NCT04584829 https://ClinicalTrials.gov/show/NCT04566688 https://ClinicalTrials.gov/show/NCT04753879 https://ClinicalTrials.gov/show/NCT04753879 https://ClinicalTrials.gov/show/NCT04862455 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT050306691
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IDIImmab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma  KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na 8 Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01AKEYMAKER-U014)  KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) None or With Pembrolizumab (USC Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U011)  Lenvatinic (67080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009)  Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Amit-PD-L1 Therapy and Lenvatinib Mith Pembrolizumab (MK-3476) vs. Standard Chemotherapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma  LUT-200 Alona and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors  MUIt-agent Low Dose Chemotherapy GAX-Cl Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer  Multi-agent Low Dose Chemotherapy GAX-Cl Followed by Olaparib	Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04482953 https://ClinicalTrials.gov/show/NCT04584829 https://ClinicalTrials.gov/show/NCT04566688 https://ClinicalTrials.gov/show/NCT0455379 https://ClinicalTrials.gov/show/NCT0453879 https://ClinicalTrials.gov/show/NCT045036051 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT0446238 https://ClinicalTrials.gov/show/NCT043200691 https://ClinicalTrials.gov/show/NCT043200691 https://ClinicalTrials.gov/show/NCT043200691
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)  [10102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [10102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [10102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [10112 With Pembrolizumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma  KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na tige Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01AKEYMAKER-U014)  KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) None or With Pembrolizumab (USC Schemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)  Lenvatinia (E7080/MK-7902) in Comination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed Atter Platinum Therapy and Immunotherapy (MK-7902-009)  Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy  Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma  LTY-200 Alono and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors  MUIti-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Duclal Cancer  Multi-agent Low Dose Chemotherapy (Avanced Rectal Cancer  NBTXR3, Radiation Thera	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y Y Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04482953 https://ClinicalTrials.gov/show/NCT04892953 https://ClinicalTrials.gov/show/NCT0456688 https://ClinicalTrials.gov/show/NCT045525757 https://ClinicalTrials.gov/show/NCT04753879 https://ClinicalTrials.gov/show/NCT04862455 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT043208691 https://ClinicalTrials.gov/show/NCT043200691 https://ClinicalTrials.gov/show/NCT03200691 https://ClinicalTrials.gov/show/NCT03200691 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT03200691
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [Io102 With Pembrolizumab, With or Without Chemotherapy as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy in Treating Patients With HPV Positive Advanced Cropharyngeal Squamous Cell Carcinoma  KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na (§ve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01AKEMAKER-U014)  KEYMAKER-U01 Umbrella Master Study: Sudies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)  Lenvatinit (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) s. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-09)/E7080-000-228LEAP-009; secondariation and Anti-PD-1.1 Therapy  Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemotradiation and Anti-PD-1.1 Therapy  Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma  LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors  MPDL3280A With Chemotradiation for Lung	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT033562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04892953 https://ClinicalTrials.gov/show/NCT04892953 https://ClinicalTrials.gov/show/NCT04666888 https://ClinicalTrials.gov/show/NCT04568797 https://ClinicalTrials.gov/show/NCT045388051 https://ClinicalTrials.gov/show/NCT04604245 https://ClinicalTrials.gov/show/NCT04164238 https://ClinicalTrials.gov/show/NCT04164238 https://ClinicalTrials.gov/show/NCT04164238 https://ClinicalTrials.gov/show/NCT04164238 https://ClinicalTrials.gov/show/NCT04164238 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT054808057 https://ClinicalTrials.gov/show/NCT05088057 https://ClinicalTrials.gov/show/NCT05088057 https://ClinicalTrials.gov/show/NCT05088057
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na 6 Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-75-01AKEYMAKER-U014) KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) Lenvatinit (67080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinith Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-09) Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Metal Cell Carcinoma LVT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors Multi-agent Low Dose Chemothera	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y Y Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04892953 https://ClinicalTrials.gov/show/NCT0466688 https://ClinicalTrials.gov/show/NCT02525757 https://ClinicalTrials.gov/show/NCT0453879 https://ClinicalTrials.gov/show/NCT045388051 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05030632 https://ClinicalTrials.gov/show/NCT05030634 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT03631615 https://ClinicalTrials.gov/show/NCT04177875
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)  IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [10102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [plilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma  KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na tige Participants With Advanced Non-small Cell Lung Cancer (MSCLC) (MK-3475-01AKEYMAKER-U014)  KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) None or With Pembrolizumab (USC Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01KEYMAKER-U017)  Lenvatinia (E7080MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed Atter Platinum Therapy and Immunotherapy (MK-7902-009)  Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy  Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma  LTY-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors  Multi-anies Model Predicts Efficacy of Properative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer  MUlti-anies Model Predicts Efficacy of Properative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer  NETXRX, Radiati	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y Y Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04482953 https://ClinicalTrials.gov/show/NCT04666688 https://ClinicalTrials.gov/show/NCT04566688 https://ClinicalTrials.gov/show/NCT04753879 https://ClinicalTrials.gov/show/NCT04568051 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05030631 https://ClinicalTrials.gov/show/NCT05030631 https://ClinicalTrials.gov/show/NCT050200691 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05088057 https://ClinicalTrials.gov/show/NCT05088057 https://ClinicalTrials.gov/show/NCT05088057 https://ClinicalTrials.gov/show/NCT05088057
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [Io102 With Pembrolizumab, With or Without Chemotherapy as First-line Treatment of Metastatic NSCLC [IO102 With Pembrolizumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Toropharyngeal Squamous Cell Carcinoma KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na (§ Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-9-10 AKEYMAKER-U014) KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) Lenvatnitic (F080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-09) Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma LVT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors MUIS-mics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Adva	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y Y Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04892953 https://ClinicalTrials.gov/show/NCT04584829 https://ClinicalTrials.gov/show/NCT04566688 https://ClinicalTrials.gov/show/NCT045525757 https://ClinicalTrials.gov/show/NCT04552879 https://ClinicalTrials.gov/show/NCT045039632 https://ClinicalTrials.gov/show/NCT04862455 https://ClinicalTrials.gov/show/NCT040462486 https://ClinicalTrials.gov/show/NCT045039632 https://ClinicalTrials.gov/show/NCT03200691 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT03631615 https://ClinicalTrials.gov/show/NCT04477875 https://ClinicalTrials.gov/show/NCT044717875 https://ClinicalTrials.gov/show/NCT044717875 https://ClinicalTrials.gov/show/NCT04471875 https://ClinicalTrials.gov/show/NCT04471875 https://ClinicalTrials.gov/show/NCT03631615 https://ClinicalTrials.gov/show/NCT044717875 https://ClinicalTrials.gov/show/NCT044717875 https://ClinicalTrials.gov/show/NCT044717875 https://ClinicalTrials.gov/show/NCT044717875 https://ClinicalTrials.gov/show/NCT044717875 https://ClinicalTrials.gov/show/NCT044717875 https://ClinicalTrials.gov/show/NCT04477875 https://ClinicalTrials.gov/show/NCT04477875 https://ClinicalTrials.gov/show/NCT04477875 https://ClinicalTrials.gov/show/NCT04477875
Checkpoint inhibitor	LaryngealHypopharyngeal Carcinoma Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)  [10102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [10102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [10102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC [10102 With Pembrolizumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Cropharyngeal Squamous Cell Carcinoma  KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-ratige Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-70-1AKEYMAKER-U014)  KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) None or With Pembrolizumab (Schemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)  Lenvatnib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatnib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed Atter Platinum Therapy and Immunotherapy (MK-7902-099/E7080-0600-228/LEAP-09)  Local Consolidative Therapy and Durivalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Threapy  Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma  LTY-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors  Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer  Neoadjuvant Anti-PD-1 Ant	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y Y Y	https://ClinicalTrials.gov/show/NCT03354962 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03562871 https://ClinicalTrials.gov/show/NCT03799445 https://ClinicalTrials.gov/show/NCT04165070 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04165798 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04428151 https://ClinicalTrials.gov/show/NCT04482953 https://ClinicalTrials.gov/show/NCT04584829 https://ClinicalTrials.gov/show/NCT0466688 https://ClinicalTrials.gov/show/NCT0456688651 https://ClinicalTrials.gov/show/NCT04753879 https://ClinicalTrials.gov/show/NCT04568051 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT04164238 https://ClinicalTrials.gov/show/NCT04104238 https://ClinicalTrials.gov/show/NCT05039632 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT05420584 https://ClinicalTrials.gov/show/NCT03401615 https://ClinicalTrials.gov/show/NCT03631615 https://ClinicalTrials.gov/show/NCT04177875 https://ClinicalTrials.gov/show/NCT04177875 https://ClinicalTrials.gov/show/NCT041717875 https://ClinicalTrials.gov/show/NCT041717875 https://ClinicalTrials.gov/show/NCT041717875

Checkpoint inhibitor Checkpoint inhibitor	Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IllA-N2 Non-Small-Cell Lung Cancer	Y		https://ClinicalTrials.gov/show/NCT04379739 https://ClinicalTrials.gov/show/NCT04422392
Checkpoint inhibitor	Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients	Y		https://ClinicalTrials.gov/show/NCT05060471
Checkpoint inhibitor	Neoadjuvant PD-1 Inhibitor, Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based Chemotherapy in Locally Advanced Upper	Υ		https://ClinicalTrials.gov/show/NCT05400070
Checkpoint inhibitor	Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity	Y		https://ClinicalTrials.gov/show/NCT04672317
Checkpoint inhibitor	or Oropharyngeal Squamous Cell Carcinoma (OOC-002)	Y		https://ClinicalTrials.gov/show/NCT05098119
Checkpoint inhibitor Checkpoint inhibitor	Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)  Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural	Y		https://ClinicalTrials.gov/show/NCT04676997 https://ClinicalTrials.gov/show/NCT04713761
	Mesothelioma Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet			
Checkpoint inhibitor	Chemotherapy in Non-Small Cell Lung Cancer  Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced	Y		https://ClinicalTrials.gov/show/NCT03348904
Checkpoint inhibitor	NSCLC Nivolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced	Y		https://ClinicalTrials.gov/show/NCT04043195
Checkpoint inhibitor	Stage IIIA/B Non-Small Cell Lung Carcinoma  Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline	Y		https://ClinicalTrials.gov/show/NCT02434081
Checkpoint inhibitor	Resectable Pancreatic Cancer  Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid	Y		https://ClinicalTrials.gov/show/NCT03970252
Checkpoint inhibitor	Tumors  Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in	Y		https://ClinicalTrials.gov/show/NCT03585465
Checkpoint inhibitor	Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)  Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma	Y	V	https://ClinicalTrials.gov/show/NCT03342352
Checkpoint inhibitor Checkpoint inhibitor	Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer	Y	т	https://ClinicalTrials.gov/show/NCT03743662 https://ClinicalTrials.gov/show/NCT05014815
Checkpoint inhibitor	Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-	Y		https://ClinicalTrials.gov/show/NCT02591615
Checkpoint inhibitor	Line NSCLC Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer	Υ		https://ClinicalTrials.gov/show/NCT04516616
Checkpoint inhibitor Checkpoint inhibitor	PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients	Y		https://ClinicalTrials.gov/show/NCT04815408 https://ClinicalTrials.gov/show/NCT03907826
Checkpoint inhibitor	PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer	Υ		https://ClinicalTrials.gov/show/NCT04833387
Checkpoint inhibitor	PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer	Υ		https://ClinicalTrials.gov/show/NCT05311566
Checkpoint inhibitor Checkpoint inhibitor	PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene Mutation Positive Advanced NSCLC PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced	Y	Y	https://ClinicalTrials.gov/show/NCT04322890 https://ClinicalTrials.gov/show/NCT03427827
	Nasopharyngeal Carcinoma  PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal			
Checkpoint inhibitor	Carcinoma  PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal	Y		https://ClinicalTrials.gov/show/NCT04907370
Checkpoint inhibitor	Carcinoma  PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction	Y	Y	https://ClinicalTrials.gov/show/NCT03619824
Checkpoint inhibitor Checkpoint inhibitor	Cancer	Y		https://ClinicalTrials.gov/show/NCT05033392 https://ClinicalTrials.gov/show/NCT04144569
Checkpoint inhibitor	PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab for Patients With Recurrent/Metastatic	Y		https://ClinicalTrials.gov/show/NCT04144569
Checkpoint inhibitor	Nasopharyngeal Carcinoma After Failure of First Line Chemotherapy  PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-	Y	Y	https://ClinicalTrials.gov/show/NCT03774732
	small Cell Lung Cancer PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced			
Checkpoint inhibitor	ESCC ESCC	Υ		https://ClinicalTrials.gov/show/NCT05357846
	PD 1 Inhibitor Combined With Negodiuvent Chemotherapy in Subjects With Reseatable Legally			
Checkpoint inhibitor	PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma	Y		
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor		Y Y Y		
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintilimab Chemoradiotherapy for Locally Advanced Rectal Cancer	Y Y Y		https://ClinicalTrials.gov/show/NCT04809775 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04304205
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintilimab Chemoradiotherapy for Locally Advanced Rectal Cancer PD1 Antibody Toripalimab and Chemoradiotherapy for dMMRMSI-H Locally Advanced Colorectal Cancer	Y Y		https://ClinicalTrials.gov/show/NCT04809775 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04304205 https://ClinicalTrials.gov/show/NCT04301557
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-L1 PET Imaging During Neoadjuvant (ChemoRadiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintlimat Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for MMR/MSH-H Locally Advanced Colorectal Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1	Y Y Y		https://ClinicalTrials.gov/show/NCT04809778 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04304209 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT05180734
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sinthimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Torigalimab and Chemoradiotherapy for dMRR/MSH-H Locally Advanced Colorectal Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Pembrolizumat (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants	Y Y Y Y		https://ClinicalTrials.gov/show/NCT04304209 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT05180734 https://ClinicalTrials.gov/show/NCT03064854
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer PD1 Antibody Sintlimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Castric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants	Y Y Y Y Y Y Y Y		https://ClinicalTrials.gov/show/NCT04809779 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04304209 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT05180734 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03675737
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1 PD-1 Impling During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for dMMRAMSI-H Locally Advanced Colorectal Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PD1CO In Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroscophageal Junction (GEJ) Adenocarcinoma (MK-3475-895)KEYNOTE-859) Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859)KEYNOTE-859)-China Extension	Y Y Y Y		https://ClinicalTrials.gov/show/NCT04809779 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04304209 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT05180734 https://ClinicalTrials.gov/show/NCT03064854
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PD1 Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)	Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809779 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04304209 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT05180734 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03675737
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antbody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer PD1 Antbody Toripalimab and Chemoradiotherapy for MMR/RMS-IH Locally Advanced Colorectal Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastaic NSCLC Patients Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859) Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859) China Extension Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally	Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809776 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT036864854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT03675737
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PET Imaging During Neoadjuvant (ChemoRadiotherapy in Esophageal and Rectal Cancer PD1 Ambbody Sintilimab Chemoradiotherapy for Incastly Advanced Rectal Cancer PD1 Ambbody Torigalimab and Chemoradiotherapy for dMMR/MSH-II Locally Advanced Colorectal Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859) Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859)-China Extension Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-830KEYNOTE-839)-China	Y Y Y Y Y Y Y Y		https://ClinicalTrials.gov/show/NCT04809779 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT05180734 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT030675737 https://ClinicalTrials.gov/show/NCT04859582
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1 IPET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintlimat Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for MMRAMSH-IH Locally Advanced Colorectal Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3478-859KEYNOTE-859) Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) 50% Locally Advanced NSCLC PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and	Y Y Y Y Y Y Y Y		https://ClinicalTrials.gov/show/NCT04809779 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT03833167 https://ClinicalTrials.gov/show/NCT03833167
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PD-1 PD-1 PD-1 PD-1 PD-1 PD-1 PD-1 PD-	Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809776 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04304205 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT0364854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT0485858
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1 IPET imaging During Weoadjuvant (ChemoRadiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintlimat Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer PD1 Antibody Toripalimab and Chemoradiotherapy for AdmR/MS-IH Locally Advanced Colorectal Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Extension Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) Pembrolizumab Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) 50% Locally Advanced NSCLC Pembrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumab Combination With Decilabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Pembrolizumab In Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy	Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809776 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04304205 https://ClinicalTrials.gov/show/NCT0430155734 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT030675737 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04153734 https://ClinicalTrials.gov/show/NCT04153734 https://ClinicalTrials.gov/show/NCT04153734 https://ClinicalTrials.gov/show/NCT04153734 https://ClinicalTrials.gov/show/NCT04153734
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antbody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antbody Toripalimab and Chemoradiotherapy for MMR/MSH-IH Locally Advanced Colorectal Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastait on NSCLC Patients Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-80/KEYNOTE-830) Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-80/KEYNOTE-830) Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced NSCLC Pembrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults	Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809776 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04504555 https://ClinicalTrials.gov/show/NCT0301655 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04153734 https://ClinicalTrials.gov/show/NCT04153734 https://ClinicalTrials.gov/show/NCT04453586 https://ClinicalTrials.gov/show/NCT044585682 https://ClinicalTrials.gov/show/NCT0344585682 https://ClinicalTrials.gov/show/NCT03471748 https://ClinicalTrials.gov/show/NCT03471748
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PD-1 PD-1 PD-1 PD-1 PD-1 PD-1 PD-1 PD-	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809776 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04301567 https://ClinicalTrials.gov/show/NCT04301567 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT03445856 https://ClinicalTrials.gov/show/NCT03445856 https://ClinicalTrials.gov/show/NCT0347546 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT05281003
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1 IPET imaging During Neoadjuvant (ChemoRadiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Pembrolizumath (IK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (IMK-3475-859/KEYNOTE-859) Pembrolizumath (IMK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (IMK-3475-859/KEYNOTE-859) China Extension Pembrolizumath (IMK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (IMK-3475-830/KEYNOTE-630) Pembrolizumab (IMK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (IMK-3475-830/KEYNOTE-630) Pembrolizumab Pilatinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) 50% Locally Advanced NSCLC Pembrolizumab Combination With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumab Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Pembrolizumab In Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy Pembrolizumab With Chemotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 50 % Pembrolizumab With Chemotherap	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809776 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04301567 https://ClinicalTrials.gov/show/NCT04301567 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT03445856 https://ClinicalTrials.gov/show/NCT03445856 https://ClinicalTrials.gov/show/NCT0347546 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT05281003
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1 InpET imaging During Neoadjuvant (ChemoRadiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Michael Cancer Pd1 Combined With Chemotherapy for Adjuvant Michael Cancer Gastric or Gastroseophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859) Pembrolizumath (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroseophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859) China Extension Pembrolizumath (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-830KEYNOTE-630) Pembrolizumath Platinum Doublets Without Radiation for Programmen Death-ligand 1 (PD-L1) 50% Locally Advanced NSCLC Pembrolizumath Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumath in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Pembrolizumath in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Pembrolizumab in Treating Patients With Hormone Receptor Positive, Loc	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809776 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04304205 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04153734 https://ClinicalTrials.gov/show/NCT02819752 https://ClinicalTrials.gov/show/NCT02819752 https://ClinicalTrials.gov/show/NCT02971748 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT033608904 https://ClinicalTrials.gov/show/NCT033608906 https://ClinicalTrials.gov/show/NCT03410784
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1 IPET imaging During Neoadjuvant (ChemoRadiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Unselected, Metastatic NSCLC Patients Gastric or Gastroes (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-559KEYNOTE-659) Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-659KEYNOTE-659) China Extension Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630KEYNOTE-630) Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630KEYNOTE-630) Pembrolizumab (MK-3475) Wersus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630KEYNOTE-630) Pembrolizumab Combination With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumab Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Advilts Pembrolizumab With Chemoth	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809776 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT03445856 https://ClinicalTrials.gov/show/NCT03947504 https://ClinicalTrials.gov/show/NCT02971748 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT03608906 https://ClinicalTrials.gov/show/NCT033608906 https://ClinicalTrials.gov/show/NCT03407844 https://ClinicalTrials.gov/show/NCT03407844 https://ClinicalTrials.gov/show/NCT03407844 https://ClinicalTrials.gov/show/NCT03407844 https://ClinicalTrials.gov/show/NCT03407844 https://ClinicalTrials.gov/show/NCT03407844 https://ClinicalTrials.gov/show/NCT03407844 https://ClinicalTrials.gov/show/NCT03407844
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Michael Cancer Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859) Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859)-Chinae Extension Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-830KEYNOTE-830) Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Chemotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Pembrolizumab in Combination With Deci	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809776 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04304205 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04858582 https://ClinicalTrials.gov/show/NCT034158581003 https://ClinicalTrials.gov/show/NCT02917148 https://ClinicalTrials.gov/show/NCT03410784 https://ClinicalTrials.gov/show/NCT0457504 https://ClinicalTrials.gov/show/NCT04547504 https://ClinicalTrials.gov/show/NCT04547504 https://ClinicalTrials.gov/show/NCT04517504 https://ClinicalTrials.gov/show/NCT04517504 https://ClinicalTrials.gov/show/NCT04517504 https://ClinicalTrials.gov/show/NCT04517504
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1 IPET Imaging During Neoadjuvant (ChemoRadiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer PD1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Pembrolizumath (MK-3475) Elus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859) Pembrolizumath (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859)-China Extension Pembrolizumath (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-830KEYNOTE-630) Pembrolizumath (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-830KEYNOTE-630) Pembrolizumath Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) 50% Locally Advanced NSCLC Pembrolizumath Combination With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumath Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Pembrolizumath in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy Pembrolizumab With Chemotherapy for Poorty Chemo-responsive Thyroid and Salivary Gland Tumors Pembrolizumab With Chemotherapy for Poorty Chem	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809776 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04301551 https://ClinicalTrials.gov/show/NCT04301551 https://ClinicalTrials.gov/show/NCT03604854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04845858 https://ClinicalTrials.gov/show/NCT04971748 https://ClinicalTrials.gov/show/NCT04971748 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT03608905 https://ClinicalTrials.gov/show/NCT036153266 https://ClinicalTrials.gov/show/NCT036153266 https://ClinicalTrials.gov/show/NCT036153266 https://ClinicalTrials.gov/show/NCT036153266
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PDF1 Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sinthimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Torigalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Torigalimab and Chemoradiotherapy for MMR/MSH-H Locally Advanced Colorectal Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Pd1 (MK-3475) Fulso Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Pembrolizumab (MK-3475) Fulso Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-859/KEYNOTE-859)-China Extension Pembrolizumab Pilatium Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) 50% Locally Advanced NSCLC Pembrolizumab in Treating Patients With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy Pembrolizumab With Chemotherapy of Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Pertoneal an	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809776 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04304205 https://ClinicalTrials.gov/show/NCT0430155737 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04153734 https://ClinicalTrials.gov/show/NCT04153734 https://ClinicalTrials.gov/show/NCT02819752 https://ClinicalTrials.gov/show/NCT02819752 https://ClinicalTrials.gov/show/NCT03410784 https://ClinicalTrials.gov/show/NCT04547504 https://ClinicalTrials.gov/show/NCT03410784 https://ClinicalTrials.gov/show/NCT03410784 https://ClinicalTrials.gov/show/NCT03410784 https://ClinicalTrials.gov/show/NCT03410784 https://ClinicalTrials.gov/show/NCT03410784 https://ClinicalTrials.gov/show/NCT03615326 https://ClinicalTrials.gov/show/NCT03615326
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer PD1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastaite NSCLC Patients Pembrolizumat (MK-3475) Flus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859) Pembrolizumath (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859) China Extension Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-830KEYNOTE-630) Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced NosCLC Pembrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma Of the Head and Neck Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Pembrolizumab Plus Chemotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 50 % Pembrolizumab Plus Chemotherapy and	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809776 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT03445856 https://ClinicalTrials.gov/show/NCT02819752 https://ClinicalTrials.gov/show/NCT0281903 https://ClinicalTrials.gov/show/NCT034645656 https://ClinicalTrials.gov/show/NCT03469806 https://ClinicalTrials.gov/show/NCT034089806 https://ClinicalTrials.gov/show/NCT03410784 https://ClinicalTrials.gov/show/NCT03410784 https://ClinicalTrials.gov/show/NCT0360896 https://ClinicalTrials.gov/show/NCT036153264 https://ClinicalTrials.gov/show/NCT036153264 https://ClinicalTrials.gov/show/NCT036153264 https://ClinicalTrials.gov/show/NCT036153264 https://ClinicalTrials.gov/show/NCT036153264 https://ClinicalTrials.gov/show/NCT047251886 https://ClinicalTrials.gov/show/NCT05214222 https://ClinicalTrials.gov/show/NCT05214222 https://ClinicalTrials.gov/show/NCT05161572
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PD-1 PD-1 PD-1 PD-1 PD-1 PD-1 PD-1 PD-	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809775 https://ClinicalTrials.gov/show/NCT0456448. https://ClinicalTrials.gov/show/NCT0456448. https://ClinicalTrials.gov/show/NCT04301551 https://ClinicalTrials.gov/show/NCT04301551 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04853734 https://ClinicalTrials.gov/show/NCT02819752 https://ClinicalTrials.gov/show/NCT02819752 https://ClinicalTrials.gov/show/NCT029171748 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT03410734 https://ClinicalTrials.gov/show/NCT03410734 https://ClinicalTrials.gov/show/NCT036153264 https://ClinicalTrials.gov/show/NCT036153264 https://ClinicalTrials.gov/show/NCT047251884 https://ClinicalTrials.gov/show/NCT05211224 https://ClinicalTrials.gov/show/NCT05214223 https://ClinicalTrials.gov/show/NCT05214223 https://ClinicalTrials.gov/show/NCT05214223 https://ClinicalTrials.gov/show/NCT05161572
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PDF1 Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antibody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antibody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer PD1 Antibody Toripalimab and Chemoradiotherapy for MMR/MSH-H Locally Advanced Colorectal Cancer PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Pembrolizumab (MK-3475) Flus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-859/KEYNOTE-859)-China Extension Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-859/KEYNOTE-859)-China Extension Pembrolizumab Pilatinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) 50% Locally Advanced NSCLC PEmbrolizumab in Tombination With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy Pembrolizumab bin Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy Pembrolizumab With Chemotherapy of pembrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL 1 50 % Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peri	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809779 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859734 https://ClinicalTrials.gov/show/NCT04859734
Checkpoint inhibitor	Advanced Thoracic Esophageal Squamous Cell Carcinoma PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC PD-1.1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer Pd1 Antbody Sintlimab Chemoradiotherapy for Locally Advanced Rectal Cancer Pd1 Antbody Toripalimab and Chemoradiotherapy for Locally Advanced Rectal Cancer PD1 Antbody Toripalimab and Chemoradiotherapy for MMR/RMSH-H Locally Advanced Colorectal Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastaic NSCLC Patients Pembrolizumat (MK-3475) Elus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859) Pembrolizumata (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859KEYNOTE-859)-China Extension Pembrolizumata (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-859KEYNOTE-859)-China Extension Pembrolizumata b Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) 50% Locally Advanced NSCLC Pembrolizumato Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumato Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Pembrolizumato in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Pembrolizumato Plus Chemotherapy and pEmbrolizumatory Breast Cancer Who Are Receiving Homone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy Pembrolizumab With Chemotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 50 % Pembrolizumab With Chemotherapy and pEmbrolizum	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT04809779 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04564482 https://ClinicalTrials.gov/show/NCT04301557 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03064854 https://ClinicalTrials.gov/show/NCT03675737 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT04859582 https://ClinicalTrials.gov/show/NCT03445858 https://ClinicalTrials.gov/show/NCT05281003 https://ClinicalTrials.gov/show/NCT05281038 https://ClinicalTrials.gov/show/NCT03615326 https://ClinicalTrials.gov/show/NCT03615326 https://ClinicalTrials.gov/show/NCT03615326 https://ClinicalTrials.gov/show/NCT04705184223 https://ClinicalTrials.gov/show/NCT04705184223 https://ClinicalTrials.gov/show/NCT05161572 https://ClinicalTrials.gov/show/NCT05161572

Checkpoint inhibitor	Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma	Y		https://ClinicalTrials.gov/show/NCT02899195
Checkpoint inhibitor	Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer	Y		https://ClinicalTrials.gov/show/NCT04107077
Checkpoint inhibitor	Phase II, Multi-center, Open-label, Randomized Trial on Efficacy and Safety of Neoadjuvant Long-course Chemoradiation Plus Tislelizumab in Mid-low Locally Advanced Rectal Cancer	Y	Υ	https://ClinicalTrials.gov/show/NCT05245474
Checkpoint inhibitor	Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma	Y		https://ClinicalTrials.gov/show/NCT03707509
Checkpoint inhibitor	Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)	Y		https://ClinicalTrials.gov/show/NCT04385368
Checkpoint inhibitor	Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and	Y		https://ClinicalTrials.gov/show/NCT04202809
· ·	Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.  PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant			-
Checkpoint inhibitor	Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer	Y		https://ClinicalTrials.gov/show/NCT03740893
Checkpoint inhibitor	Placebe-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naive Limited-Stage Small Cell Lung Canacr (LS-SCLO) (MK 7339-013/KEYLYNK-013)	Y	Υ	https://ClinicalTrials.gov/show/NCT04624204
Checkpoint inhibitor	Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy	Y		https://ClinicalTrials.gov/show/NCT03904108
Checkpoint inhibitor	Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer	Y		https://ClinicalTrials.gov/show/NCT04205812
Checkpoint inhibitor	Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies		Y	https://ClinicalTrials.gov/show/NCT04902040
Checkpoint inhibitor	Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal	Y	Y	https://ClinicalTrials.gov/show/NCT04435197
Checkpoint inhibitor	Squamous Cell Carcinoma Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases		Y	https://ClinicalTrials.gov/show/NCT04793737
Checkpoint inhibitor	Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squmous Cell Carcinoma of Esophageus	Y		https://ClinicalTrials.gov/show/NCT03792347
Checkpoint inhibitor	Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC	Y		https://ClinicalTrials.gov/show/NCT03478488
Checkpoint inhibitor	Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma	Y		https://ClinicalTrials.gov/show/NCT03930498
Checkpoint inhibitor	QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy	Y		https://ClinicalTrials.gov/show/NCT03167177
Checkpoint inhibitor	QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-	Y		https://ClinicalTrials.gov/show/NCT03169764
	1/PD-L1 Therapy			
Checkpoint inhibitor	QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy	Y		https://ClinicalTrials.gov/show/NCT03197571
Checkpoint inhibitor	Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer		Υ	https://ClinicalTrials.gov/show/NCT03601455
Checkpoint inhibitor Checkpoint inhibitor	Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer		Y Y	https://ClinicalTrials.gov/show/NCT03150836 https://ClinicalTrials.gov/show/NCT04837209
Checkpoint inhibitor	Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized,	Y		https://ClinicalTrials.gov/show/NCT04230759
Checkpoint inhibitor	Phase II Trial of the German Anal Cancer Study Group  Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic	Y		https://ClinicalTrials.gov/show/NCT05233696
	TNBC  RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With	'	V	
Checkpoint inhibitor	Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy  Randomized Phase II Trial of a PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive		Y	https://ClinicalTrials.gov/show/NCT02880345
Checkpoint inhibitor	Concurrent Chemoradiotherapy(RHAPSODY)	Y		https://ClinicalTrials.gov/show/NCT04494009
Checkpoint inhibitor	Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer	Y		https://ClinicalTrials.gov/show/NCT04052113
Checkpoint inhibitor Checkpoint inhibitor	Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.  Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC	Y		https://ClinicalTrials.gov/show/NCT05142709 https://ClinicalTrials.gov/show/NCT05307198
опоокрони пинької	reduit rulely intedict chemotherapy combined that rule 1 5 1 rulebody for moc 2 1 to			nape.//oiimodi/maio.gov/oiiow//to/10000//100
Checkpoint inhibitor	REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4	Y		https://ClinicalTrials.gov/show/NCT03515629
	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell	Y	Y	
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary		Y	https://ClinicalTrials.gov/show/NCT03317327
Checkpoint inhibitor Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck	Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289209
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Timons Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer	Y	Y	https://ClinicalTrials.gov/show/NCT03515629 https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289209 https://ClinicalTrials.gov/show/NCT03127007
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Safety and Efficacy of Aterolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.	Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289209 https://ClinicalTrials.gov/show/NCT03127007
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Safety and Efficacy of Alezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lervatinib (E7080MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoemobicization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)	Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289209
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer  Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.  Safety and Efficacy of Levation (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-6000-318LE-R-012)  Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK- 3476-651)	Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289209 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03356860
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Safety and Efficacy of Alezoilizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lervatinib (E7880MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-6900-318/LEAP-012) Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-	Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289208 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03356860 https://ClinicalTrials.gov/show/NCT04246177
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lervatinib (27080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-6000-318LEA-012) Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK- 3475-651) Safety and Efficacy of Restfanlimat (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After	Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289209 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03356860 https://ClinicalTrials.gov/show/NCT04246177 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT04463771
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell Co of the Head and Neck Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-017/E7080-6000-318/LEAP-012) Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK- 3475-651) Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platnum-based Chemotherapy. Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Of Without Other Anti-Cancer	Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289209 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03356860 https://ClinicalTrials.gov/show/NCT04246177
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Nock Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell Co of the Head and Neck Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lovarium (2016) Pradicipants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-790-2012/E7080-6000-318LE-RP-012) Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK- 3476-651) Safety and Efficacy of Restfanlimat (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer With of Without Other Anti-Cancer Immunotherapy Agents in Patients With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizuma	Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289209 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03356860 https://ClinicalTrials.gov/show/NCT04246177 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT04463771
Checkpoint inhibitor	Antibody) Versus Pembroitzumab Monotherapy in Patients With Lung Cancer REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembroitzumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Safety and Efficacy of Alezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2() and Triple Negative Breast Cancer. Safety and Efficacy of Lenvatinin (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-6000-318/LEAP-012) Safety and Efficacy of Pembrolizumab (MK-3475) Flus Binimethib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651) Safety and Efficacy of Rebtfanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.  Safety And Efficacy Study of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agent Shard Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Tarylace Malignancies Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-207680) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-207680) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-207680) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-207680) as First-line	Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289208 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03356860 https://ClinicalTrials.gov/show/NCT04246177 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Nock Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell Co of the Head and Neck Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Preoperative Radio-chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lovalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lenvalumib (27080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-01)zE7080-e000-318LEA-012) Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK- 3476-651) Safety and Efficacy of Restfanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Plastnum-based Chemotherapy. Safety and Efficacy Study of Avelumab Plus Chemotherapy With or Without Other Anti-Cancer Immunotherapy Agents in Patients With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006E7080-0000-315LEAP-006)-China Extension Study Non-small Cell Lung Cance	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289209 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03356860 https://ClinicalTrials.gov/show/NCT04246177 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT04463771 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT04469331 https://ClinicalTrials.gov/show/NCT04716933
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell Co of the Head and Neck Safety and Efficacy of Alezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lenvalumib (E7080MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012E/7080-0000-318/LEAP-012) Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimethib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimethib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651) Safety and Efficacy of Rebrosity (Incurable Non-metastatic Hepatocellular Patisfum-based Chemotherapy. Safety and Efficacy of Pembrolizumab (MK-3475) Incurrence in Patisfum-based Chemotherapy. Safety and Efficacy Study of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents in Patients With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TMBC) (MK-3475) With or Without Lenvalnib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-0300-315/LEAP-006)-China Extension Study Non-small Cell Lung Cancer (MK-7902-006/E7080-0300-315/LEAP-006)-China Extension Study Non-small Cell Lung Cancer (MK-7902-006/E7080-0300-315/LEAP-006)-China Extension Study Non-small Cell Lung Cancer (Ink-7902-006/E7080-0300-315/LEAP-006)-China Extension Study Non-small Cell Lung Cancer (Ink-7902-006/E7080-0300-315/LEAP-006)-C	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289209 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT0356860 https://ClinicalTrials.gov/show/NCT04246177 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT04463771 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT02622074
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Turnors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell Co of the Head and Neck Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lovalumin E(7380,MK-7802) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-0900-318/LEAP-012) Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-851) Safety and Efficacy of Reitfanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Wino Have Progressed on or After Platanum-based Chemotherapy Agents In Paticipants With Transarterial Chemotherapy Safety And Efficacy Study of Avelumab Plus Chemotherapy With or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TMBC) (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-0000-315/LEAP-006)-China Extension Study Safety and Efficacy Study of Pembrolizumab First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-0000-315/LEAP-006)-China Extension Study Safety and Efficacy Study of Pembrolizon-Safety and E	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y		https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289208 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03156860 https://ClinicalTrials.gov/show/NCT04246177 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell Co of the Head and Neck Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lervatinib (27080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-01)z/E7080-e900-318/LEA-P0-12) Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK- 3476-681) Safety and Efficacy of Restfanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Plastnum-based Chemotherapy. Safety And Efficacy Study of Avelumab Plus Chemotherapy With or Without Other Anti-Cancer Immunotherapy Agents in Patients With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Non-small Cell Lung Cancer (MK-7902-006/E7080-000-315/LEAP-006)-China Extension Study Non-small Cell Lung Cancer (MK-7902-006/E7080-000-003-000-315/LEAP-006)-China Extension Study Non-small Cell Lung Cancer (MK-7902-006/E7080-0000-315/LEAP-006)-China Extension Study Safety and Efficacy Study of Pembrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinic (MK-7902/E7080) as First-line Intervention in Adults With Meta	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0317327 https://ClinicalTrials.gov/show/NCT03289208 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT04246177 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell Co of the Head and Neck Safety and Efficacy of Alezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lovarium (2708) Practice of Safety and Efficacy of Lovarium (2708) Practice of Safety and Efficacy of Lovarium (2708) Practice of Safety and Efficacy of Levarium (2708) Practice of Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK- 3475-651) Safety and Efficacy of Restifanlimat (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Plastrum-based Chemotherapy. Safety and Efficacy Study of Aveurab Plus Chemotherapy With or Without Other Anti-Cancer Immunotherapy Agents in Patients With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0317327 https://ClinicalTrials.gov/show/NCT02289205 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03356860 https://ClinicalTrials.gov/show/NCT04246177 https://ClinicalTrials.gov/show/NCT0433774264 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell Co of the Head and Neck Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Preoperative Radio-chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lovalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lenvalumib (£7080.MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902.012/E7080.e000-318/LEA-P012) Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK- 3476-851) Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents in Patients With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Non-small Cell Lung Cancer (MK-7902-206/E7080-3000-315/LEAP-006)-China Extension Study Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-206/E7080-0000-315/LEAP-006)-China Extension Study Safety and Efficacy Study of Pembrolizumab (MK-30000-315/LEAP-006)-China Extension Study Safety and Efficacy Study of Pembrolizumab (MK-30000-315/LEAP-006)-China Extension	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT0289206 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03356860 https://ClinicalTrials.gov/show/NCT04246177 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell Co of the Head and Neck Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Levation (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-01)z/E7080-6000-318/LEA-P0-12) Safety and Efficacy of Levation (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-01)z/E7080-6000-318/LEA-P0-12) Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK- 3476-651) Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Plastrum-based Chemotherapy. Safety And Efficacy Study of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents in Patients With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-379) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-379) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3790) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3790) in Combination With Metastatic Nonsquamous Non-small Cell L	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0317327 https://ClinicalTrials.gov/show/NCT03289205 https://ClinicalTrials.gov/show/NCT0317207 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03356866 https://ClinicalTrials.gov/show/NCT04246177 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT0322074 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT03812545 https://ClinicalTrials.gov/show/NCT03812545 https://ClinicalTrials.gov/show/NCT03764593
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell Co of the Head and Neck Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lovarium (2006) Provided to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lenvatinib (27080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-6000-318/LEAP-012) Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK- 3475-651) Safety and Efficacy of Retifanlimat (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Plastrum-based Chemotherapy. Safety and Efficacy Study of Aveuturab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents in Patients With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT02289205 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT0356860 https://ClinicalTrials.gov/show/NCT04246177 https://ClinicalTrials.gov/show/NCT04463771 https://ClinicalTrials.gov/show/NCT04463771 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Turnors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell Co of the Head and Neck Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Levation (E7080MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-0900-318/LEAP-012) Safety and Efficacy of Pembrolizumab (MK-3475) bit Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-0900-318/LEAP-012) Safety and Efficacy of Pembrolizumab (MK-3475) bit Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-0900-318/LEAP-012) Safety and Efficacy of Pembrolizumab (MK-3475) bit Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-0900-318/LEAP-012) Safety and Efficacy of Resifanilimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy Agents in Patients With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TMBC) (MK-3475) Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TMBC) (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-0000-315/LEAP-006)-China Extension Study Safety	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0317327 https://ClinicalTrials.gov/show/NCT0289206 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03356860 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT047264593 https://ClinicalTrials.gov/show/NCT03812549 https://ClinicalTrials.gov/show/NCT03764593 https://ClinicalTrials.gov/show/NCT02764593 https://ClinicalTrials.gov/show/NCT02764593
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell Co of the Head and Neck Safety and Efficacy of Alezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Alezolizumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lenvatinib (E7080MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-01)2:F098-0000-318 (LEA-012) Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK- 3475-651) Safety and Efficacy of Restfanlimab (INCMGA0012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Plasfium-based Chemotherapy. Safety And Efficacy Study of Avelumab Plus Chemotherapy With or Without Other Anti-Cancer Immunotherapy Agents in Patients With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475- 173/KEYNOTE-173) Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Non-small Cell Lung Cancer (MK-7902-008-7780-00-003-1516-LEA-006)-China Extension Study Safety and Efficacy Study of Pembroxed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902-7780) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-008-7780-000-003-1516-LEA-006)-China Extension Study Safety and Eff	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT03289206 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT033568606 https://ClinicalTrials.gov/show/NCT04246177 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT04716933
Checkpoint inhibitor	Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Reirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell Co of the Head and Neck Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. Safety and Efficacy of Lovalumib (27080MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-01)z/E7080-6000-318/LEA-012) Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK- 3476-651) Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. Safety And Efficacy Study Of Avelumab Plus Chemotherapy With or Without Other Ansi-Cancer Immunotherapy Agents in Patients With Advanced Malignancies Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Research and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Research and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Research and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Research and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Pembrolizumab (MK-3475) with or Without Lenvatinib (MK-7902/E708	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT03317327 https://ClinicalTrials.gov/show/NCT03289208 https://ClinicalTrials.gov/show/NCT03127007 https://ClinicalTrials.gov/show/NCT03356860 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT03374254 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT03317496 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933 https://ClinicalTrials.gov/show/NCT04716933

Checkpoint inhibitor	Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma	Y		https://ClinicalTrials.gov/show/NCT03700476
Checkpoint inhibitor	SinTilimab After Radiation (STAR Study)		Y	https://ClinicalTrials.gov/show/NCT04167657
Checkpoint inhibitor	Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer	Y		https://ClinicalTrials.gov/show/NCT03946969
Checkpoint inhibitor Checkpoint inhibitor	Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma  Stereotactic Ablative Radiation for Oligo-Progression of Urothelial Cancer	Y		https://ClinicalTrials.gov/show/NCT03748134 https://ClinicalTrials.gov/show/NCT04131634
Checkpoint inhibitor	Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of		Υ	https://ClinicalTrials.gov/show/NCT03050554
Checkpoint inhibitor	Early Stage Non-Small Cell Lung Cancer (NSCLC) Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative		Y	
Checkpoint inhibitor	Breast Cancer			https://ClinicalTrials.gov/show/NCT03151447
Checkpoint inhibitor	Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma		Y	https://ClinicalTrials.gov/show/NCT03857815
Checkpoint inhibitor	Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma	Y		https://ClinicalTrials.gov/show/NCT04997837
Checkpoint inhibitor	Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer	Y		https://ClinicalTrials.gov/show/NCT02735239
Checkpoint inhibitor	Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma	Y		https://ClinicalTrials.gov/show/NCT04568200
Checkpoint inhibitor	Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma	Υ		https://ClinicalTrials.gov/show/NCT02807636
Checkpoint inhibitor	Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-	Y		https://ClinicalTrials.gov/show/NCT04471428
Checkpoint inhibitor	Containing Chemotherapy  Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the	Y		https://ClinicalTrials.gov/show/NCT03987867
	Advanced NSCLC Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally			
Checkpoint inhibitor	Advanced Esophageal Cancer	Y		https://ClinicalTrials.gov/show/NCT04426955
Checkpoint inhibitor	Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)	Υ		https://ClinicalTrials.gov/show/NCT04221945
Checkpoint inhibitor	Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer	Y		https://ClinicalTrials.gov/show/NCT05273814
Checkpoint inhibitor	Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to	Y		https://ClinicalTrials.gov/show/NCT04836728
	Treat Lung Cancer Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung			
Checkpoint inhibitor	Cancer	Y		https://ClinicalTrials.gov/show/NCT03944980
Checkpoint inhibitor	Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer	Υ		https://ClinicalTrials.gov/show/NCT03950154
Checkpoint inhibitor	Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK- 7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (ECO, MK-7339-001/KEYLYNK-001/ENOOT-0-43/ROG-3036)	Y		https://ClinicalTrials.gov/show/NCT03740165
Checkpoint inhibitor	Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer	Y	Y	https://ClinicalTrials.gov/show/NCT03102047
Checkpoint inhibitor	Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or	Y		https://ClinicalTrials.gov/show/NCT03164616
	Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).  Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer			
Checkpoint inhibitor	(PEARL)	Y		https://ClinicalTrials.gov/show/NCT03003962
Checkpoint inhibitor	Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High ( 50%) NSCLC Patients	Υ		https://ClinicalTrials.gov/show/NCT04470674
Checkpoint inhibitor	Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC	Y	Y	https://ClinicalTrials.gov/show/NCT04550260
Checkpoint inhibitor	Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC	Y		https://ClinicalTrials.gov/show/NCT04390763
Опоскроничний	Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)  Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or	,		The provided High Service Control of the Control of
Checkpoint inhibitor	Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects	Y		https://ClinicalTrials.gov/show/NCT03631199
Checkpoint inhibitor	Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)	Y		https://ClinicalTrials.gov/show/NCT02862457
Checkpoint inhibitor	Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-702) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)	Y		https://ClinicalTrials.gov/show/NCT02720068
Checkpoint inhibitor	Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplath-nieligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and In Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/LEAP- 0111)	Υ		https://ClinicalTrials.gov/show/NCT03898180
Checkpoint inhibitor	Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic		Υ	https://ClinicalTrials.gov/show/NCT02868632
Checkpoint inhibitor	Pancreatic Cancer Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (Mk-7339-	Y		https://ClinicalTrials.gov/show/NCT04191135
011	009/KEYLYNK-009) Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined	.,		Lucy Hopers (Fr.
Checkpoint inhibitor	Chemotherapy	Y		https://ClinicalTrials.gov/show/NCT04812002
Checkpoint inhibitor Checkpoint inhibitor	Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL	Y		https://ClinicalTrials.gov/show/NCT04821765 https://ClinicalTrials.gov/show/NCT04134247
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)	Υ		https://ClinicalTrials.gov/show/NCT02142738
Checkpoint inhibitor	Intelligence of the Control of the C	Y		https://ClinicalTrials.gov/show/NCT04634877
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally	Y	Y	https://ClinicalTrials.gov/show/MCT03040000
	Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)		ī	https://ClinicalTrials.gov/show/NCT03040999
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)	Y		https://ClinicalTrials.gov/show/NCT04895358
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475- 585/KEYNOTE-585)	Y		https://ClinicalTrials.gov/show/NCT03221426
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475- 585/KEYNOET-585)-China Extension	Y		https://ClinicalTrials.gov/show/NCT04882241
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)	Υ		https://ClinicalTrials.gov/show/NCT03036488
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475- 355/KEYNOTE-355)	Y		https://ClinicalTrials.gov/show/NCT02819518
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-	Υ		https://ClinicalTrials.gov/show/NCT03834506
• • • •	naive Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)  Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-			
Checkpoint inhibitor	naive Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension	Y		https://ClinicalTrials.gov/show/NCT04907227
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)	Y		https://ClinicalTrials.gov/show/NCT04956692
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)	Y		https://ClinicalTrials.gov/show/NCT05239741

Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT- en15)	Υ		https://ClinicalTrials.gov/show/NCT05173987
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)	Y		https://ClinicalTrials.gov/show/NCT01704287
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181K/EVNOTE-181)-China Extension Study	Υ		https://ClinicalTrials.gov/show/NCT03933449
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE- 756)	Υ		https://ClinicalTrials.gov/show/NCT03725059
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)	Υ	Υ	https://ClinicalTrials.gov/show/NCT04210115
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-04/XEYNOTE-042)	Υ		https://ClinicalTrials.gov/show/NCT02220894
Checkpoint inhibitor	Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-04/EKYNOTE-042)-China Extension Study	Υ		https://ClinicalTrials.gov/show/NCT03850444
Checkpoint inhibitor	(INIC-347-3-042/INCTTWO 1E-042/P-CHINIA EXTENSION SULDY Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)	Y	Y	https://ClinicalTrials.gov/show/NCT02934503
Checkpoint inhibitor	Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or	Y	Υ	https://ClinicalTrials.gov/show/NCT04380636
	Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)  Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and	Y		
Checkpoint inhibitor	Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma  Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus			https://ClinicalTrials.gov/show/NCT03727880
Checkpoint inhibitor Checkpoint inhibitor	Study of Perindrical with Christian United Planting Study of Perindrical Planting Study of Perindrical Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC	Y		https://ClinicalTrials.gov/show/NCT02853305 https://ClinicalTrials.gov/show/NCT04754815
	Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy			
Checkpoint inhibitor	Followed by Pembrolizumab/Nibostolimiab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006) Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults	Y		https://ClinicalTrials.gov/show/NCT05298423
Checkpoint inhibitor	With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)	Υ		https://ClinicalTrials.gov/show/NCT03515837
Checkpoint inhibitor	Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer	Υ		https://ClinicalTrials.gov/show/NCT04786964
Checkpoint inhibitor	Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)	Υ		https://ClinicalTrials.gov/show/NCT02578680
Checkpoint inhibitor	Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)- Japan Extension Study	Υ		https://ClinicalTrials.gov/show/NCT03950674
Checkpoint inhibitor	Setup of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non- Small Cell Lung Cancer (NSCLC)	Y		https://ClinicalTrials.gov/show/NCT03088540
Checkpoint inhibitor	Study of Sacituzumab Govitecan-hziy (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCL) With Progression on or After Platinum-Based Chemotherapy and Anti-programmed Death Protein 1 (PD-1)Programmed Death Ligand 1 (PD-1) Immunotherapy	Υ		https://ClinicalTrials.gov/show/NCT05089734
Checkpoint inhibitor	Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)	Υ		https://ClinicalTrials.gov/show/NCT05008224
Checkpoint inhibitor	Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer	Υ		https://ClinicalTrials.gov/show/NCT03691090
Checkpoint inhibitor	Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors	Υ		https://ClinicalTrials.gov/show/NCT04588324
Checkpoint inhibitor	Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)	Υ		https://ClinicalTrials.gov/show/NCT0255565
Checkpoint inhibitor	Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma		Υ	https://ClinicalTrials.gov/show/NCT0346589
Checkpoint inhibitor	Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy	Υ		https://ClinicalTrials.gov/show/NCT04359550
Checkpoint inhibitor	Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care	Y		https://ClinicalTrials.gov/show/NCT0339907
Checkpoint inhibitor	Following Chemotherapy in Patients With Lung Cancer [IMpower010]	Y		https://ClinicalTrials.gov/show/NCT02486718
Checkpoint inhibitor Checkpoint inhibitor	Study With Alezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer  Systemic Chemotherapy Plus PD-1 for Metastasis ICC	Y		https://ClinicalTrials.gov/show/NCT02982694 https://ClinicalTrials.gov/show/NCT0439892
Checkpoint inhibitor	Systemic Chemoditerapy Flus FD-1 for weldstasis ICC Tapestry: Addition of TGF-b and PDL-1 Inhibition to Definitive Chemoradiation in Esophageal Squamous Cell Carcinoma	Y	Υ	https://ClinicalTrials.gov/show/NCT04595149
Checkpoint inhibitor	Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment		Y	https://ClinicalTrials.gov/show/NCT03085719
				https://ClinicalTrials.gov/show/NCT04963153
Checkpoint inhibitor	With Chemotherapy and Immunotherapy  Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab),	Y		maps.//omnicarmais.gov/snow/re-104363136
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, ZEN03694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer	Y		https://ClinicalTrials.gov/show/NCT05422794
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paciltaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without	Y	Y	https://ClinicalTrials.gov/show/NCT0542279/https://ClinicalTrials.gov/show/NCT03304638
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Pacilitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-1.1 Negative	Y	Y Y	https://ClinicalTrials.gov/show/NCT0542279-https://ClinicalTrials.gov/show/NCT03304639 https://ClinicalTrials.gov/show/NCT0492904
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paciltaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer	Y		https://ClinicalTrials.gov/show/NCT0542279 https://ClinicalTrials.gov/show/NCT0330463 https://ClinicalTrials.gov/show/NCT0492904
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, ZEN03694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paciltaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-b And PDL-1 Inhibitor in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapy	Y		https://ClinicalTrials.gov/show/NCT0542279-https://ClinicalTrials.gov/show/NCT03304638-https://ClinicalTrials.gov/show/NCT0492904-https://ClinicalTrials.gov/show/NCT0250012-https://ClinicalTrials.gov/show/NCT04841256
Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paciltaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-b And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer	Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0542279 https://ClinicalTrials.gov/show/NCT0330463 https://ClinicalTrials.gov/show/NCT0492904 https://ClinicalTrials.gov/show/NCT0250012 https://ClinicalTrials.gov/show/NCT0448125 https://ClinicalTrials.gov/show/NCT0398589
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Pol-1 Inhibitor of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-b And PDL-1 Inhibitor in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRap? The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer	Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0542279 https://ClinicalTrials.gov/show/NCT0330463 https://ClinicalTrials.gov/show/NCT0492904 https://ClinicalTrials.gov/show/NCT0250012 https://ClinicalTrials.gov/show/NCT0488125 https://ClinicalTrials.gov/show/NCT0398589 https://ClinicalTrials.gov/show/NCT0500055
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, 2EN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Pacitiaxet)) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-b And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemotherapy in The Rapy The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer The Safety and Efficacy of Transarterial Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of Transarterial Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of Transarterial Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of Transarterial Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of Transarterial Chemotherapy in Patients With Locally Advanced Colon Cancer	Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0542279 https://ClinicalTrials.gov/show/NCT0330463 https://ClinicalTrials.gov/show/NCT0492904 https://ClinicalTrials.gov/show/NCT0250012 https://ClinicalTrials.gov/show/NCT04948125 https://ClinicalTrials.gov/show/NCT0398589 https://ClinicalTrials.gov/show/NCT0500055 https://ClinicalTrials.gov/show/NCT0499785
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, 2EN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paciltaxet) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-B And PD-L1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemordiation TheRapY The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma Tistellizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma	Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0542279 https://ClinicalTrials.gov/show/NCT03304631 https://ClinicalTrials.gov/show/NCT0492904 https://ClinicalTrials.gov/show/NCT0250012 https://ClinicalTrials.gov/show/NCT04948125 https://ClinicalTrials.gov/show/NCT0398589 https://ClinicalTrials.gov/show/NCT04997851 https://ClinicalTrials.gov/show/NCT04997851
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, 2EN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paciltaxet) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-B And PD-L1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemordiation TheRapY The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma Tislelizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasophanyngeal Carcinoma Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC	Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0542279-https://ClinicalTrials.gov/show/NCT03304638-https://ClinicalTrials.gov/show/NCT0492904-https://ClinicalTrials.gov/show/NCT0250012-https://ClinicalTrials.gov/show/NCT04481256-https://ClinicalTrials.gov/show/NCT0398589-https://ClinicalTrials.gov/show/NCT050055-https://ClinicalTrials.gov/show/NCT04997856-https://ClinicalTrials.gov/show/NCT04997856-https://ClinicalTrials.gov/show/NCT04907856-https://ClinicalTrials.gov/show/NCT04907856-https://ClinicalTrials.gov/show/NCT04907856-https://ClinicalTrials.gov/show/NCT04870901-https://ClinicalTrials.gov/s
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, ZEN03694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paciltaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Pol-1 Inhibitor Pembrolizumab as Maintenancer Patients Who Are PD-L1 Negative Testing the Pol-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-b And PDL-1 Inhibitor in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRap? The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein (19-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma Tislelizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy	Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT05422794 https://ClinicalTrials.gov/show/NCT03304635 https://ClinicalTrials.gov/show/NCT04929041 https://ClinicalTrials.gov/show/NCT0500121 https://ClinicalTrials.gov/show/NCT04481256 https://ClinicalTrials.gov/show/NCT04985891 https://ClinicalTrials.gov/show/NCT04997856 https://ClinicalTrials.gov/show/NCT0487090564 https://ClinicalTrials.gov/show/NCT0487090564
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, 2EN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paciltaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-B And PD-L1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemordiation TheRapY The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma Tislelizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Necadijuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy and HLX10 Versus Placebo as Adjuvant	Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0542279- https://ClinicalTrials.gov/show/NCT03304638 https://ClinicalTrials.gov/show/NCT0492904 https://ClinicalTrials.gov/show/NCT0490012- https://ClinicalTrials.gov/show/NCT0590012- https://ClinicalTrials.gov/show/NCT059055- https://ClinicalTrials.gov/show/NCT049978569- https://ClinicalTrials.gov/show/NCT049978569- https://ClinicalTrials.gov/show/NCT0490567- https://ClinicalTrials.gov/show/NCT0440567- https://ClinicalTrials.gov/show/NCT0440567- https://ClinicalTrials.gov/show/NCT04402083:
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, ZEN03694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Pacittaxet)) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-b And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemotherapy in The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein (19-1) Antibody of Advanced Unressectable Hepatocellular Carcinoma Tislelizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC Tislelizumab Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant	Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0542279- https://ClinicalTrials.gov/show/NCT0530463t https://ClinicalTrials.gov/show/NCT0492904- https://ClinicalTrials.gov/show/NCT0490912- https://ClinicalTrials.gov/show/NCT0448125t https://ClinicalTrials.gov/show/NCT0448125t https://ClinicalTrials.gov/show/NCT0499785t https://ClinicalTrials.gov/show/NCT0499785t https://ClinicalTrials.gov/show/NCT0490567- https://ClinicalTrials.gov/show/NCT0402083: https://ClinicalTrials.gov/show/NCT042083: https://ClinicalTrials.gov/show/NCT04301738
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, 2EN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paciltaxet) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-B And PD-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemotherapy in The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma Tislelizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKi-Resistant EGFR-Mutated Non-squamous NSCLC Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy Local Mithout Security (PD-1 National Security of Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy on Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy to Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy in Primary Tracheal Squamous Cell Carcinoma	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0542279 https://ClinicalTrials.gov/show/NCT03304631 https://ClinicalTrials.gov/show/NCT0492904 https://ClinicalTrials.gov/show/NCT0492904 https://ClinicalTrials.gov/show/NCT049012 https://ClinicalTrials.gov/show/NCT0498589 https://ClinicalTrials.gov/show/NCT04997856 https://ClinicalTrials.gov/show/NCT04907856 https://ClinicalTrials.gov/show/NCT044056767 https://ClinicalTrials.gov/show/NCT0440567676 https://ClinicalTrials.gov/show/NCT04401733 https://ClinicalTrials.gov/show/NCT04301733 https://ClinicalTrials.gov/show/NCT04301731 https://ClinicalTrials.gov/show/NCT04301731 https://ClinicalTrials.gov/show/NCT04301731
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paciltaxet) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-B And PD-L1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemordiation TheRapY The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma Tislellizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced masopharyngeal Carcinoma Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Treast Cancer (TNDC) Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell Carcinoma Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell Carcinoma	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0542279 https://ClinicalTrials.gov/show/NCT03304631 https://ClinicalTrials.gov/show/NCT0492904 https://ClinicalTrials.gov/show/NCT0492904 https://ClinicalTrials.gov/show/NCT049012 https://ClinicalTrials.gov/show/NCT0498589 https://ClinicalTrials.gov/show/NCT04997856 https://ClinicalTrials.gov/show/NCT04907856 https://ClinicalTrials.gov/show/NCT044056767 https://ClinicalTrials.gov/show/NCT0440567676 https://ClinicalTrials.gov/show/NCT04401733 https://ClinicalTrials.gov/show/NCT04301733 https://ClinicalTrials.gov/show/NCT04301731 https://ClinicalTrials.gov/show/NCT04301731 https://ClinicalTrials.gov/show/NCT04301731
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, ZEN03694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paciltaxat) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-1 Hospative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-B And PD-1 Inhibitor In Esophageal Squamous Cell Carcinoma Combined With Chemordiation TheRapY The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma Tisellizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma Tisellizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC Tiselizumab in Combination With Antionib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy To Patients of Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Tiple Negative Breast Cancer (TMSC) Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0542279- https://ClinicalTrials.gov/show/NCT0530463t https://ClinicalTrials.gov/show/NCT0492904- https://ClinicalTrials.gov/show/NCT0250012- https://ClinicalTrials.gov/show/NCT04481256- https://ClinicalTrials.gov/show/NCT04481256- https://ClinicalTrials.gov/show/NCT04997856- https://ClinicalTrials.gov/show/NCT04997856- https://ClinicalTrials.gov/show/NCT0440567- https://ClinicalTrials.gov/show/NCT0440567- https://ClinicalTrials.gov/show/NCT04301733- https://ClinicalTrials.gov/show/NCT04301733- https://ClinicalTrials.gov/show/NCT0471675- https://ClinicalTrials.gov/show/NCT0471675- https://ClinicalTrials.gov/show/NCT04505588- https://ClinicalTrials.gov/show/NCT045055588- https://ClinicalTrials.gov/show/NCT05055588- https://ClinicalTrials.gov/show/NCT05055588- https://ClinicalTrials.gov/show/NCT04343813-
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, 2EN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paciltaxet) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-B And PD-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemordiation TheRapy The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma Tislelizumab (PD-1 Amibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy Toripalimab as Monotherapy or Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell Carcinoma Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell Carcinoma Toripalimab Combined With Chemotherapy and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinomia Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0542279- https://ClinicalTrials.gov/show/NCT0542279- https://ClinicalTrials.gov/show/NCT0304831 https://ClinicalTrials.gov/show/NCT0492904- https://ClinicalTrials.gov/show/NCT0492904- https://ClinicalTrials.gov/show/NCT0481251- https://ClinicalTrials.gov/show/NCT0398589- https://ClinicalTrials.gov/show/NCT04997856- https://ClinicalTrials.gov/show/NCT04997856- https://ClinicalTrials.gov/show/NCT0440567- https://ClinicalTrials.gov/show/NCT0402033- https://ClinicalTrials.gov/show/NCT0401738- https://ClinicalTrials.gov/show/NCT04704567- https://ClinicalTrials.gov/show/NCT04704567- https://ClinicalTrials.gov/show/NCT04505588- https://ClinicalTrials.gov/show/NCT0470575- https://ClinicalTrials.gov/show/NCT047055588- https://ClinicalTrials.gov/show/NCT04403811- https://ClinicalTrials.gov/show/NCT04403811- https://ClinicalTrials.gov/show/NCT04458381- https://ClinicalTrials.gov/show/NCT04458381-
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paciltaxet) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-B And PD-L1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemordiation TheRapY The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma Tislellizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced maschpanyngeal Carcinoma Tislellizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Mith Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC Tislelizumab in Combination With Antionib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Treast Cancer (TNBC) Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell Carcinoma Toripalimab Thouse Therapy and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma Toripalima	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0542279- https://ClinicalTrials.gov/show/NCT0530463t https://ClinicalTrials.gov/show/NCT0492904- https://ClinicalTrials.gov/show/NCT0492904- https://ClinicalTrials.gov/show/NCT0498589- https://ClinicalTrials.gov/show/NCT0498589- https://ClinicalTrials.gov/show/NCT04997855- https://ClinicalTrials.gov/show/NCT04997856- https://ClinicalTrials.gov/show/NCT049567- https://ClinicalTrials.gov/show/NCT040567- https://ClinicalTrials.gov/show/NCT040567- https://ClinicalTrials.gov/show/NCT0405683- https://ClinicalTrials.gov/show/NCT0405588- https://ClinicalTrials.gov/show/NCT0405588- https://ClinicalTrials.gov/show/NCT0405588- https://ClinicalTrials.gov/show/NCT0405588- https://ClinicalTrials.gov/show/NCT0405588- https://ClinicalTrials.gov/show/NCT0405588- https://ClinicalTrials.gov/show/NCT046584-
Checkpoint inhibitor	With Chemotherapy and Immunotherapy Testing the Addition of Anti-Cancer Drug, ZEN03694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Pacitiaxat)) Treatment in Patients With Advanced Triple-Negative Breast Cancer Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-1 Repative Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer TGF-b And PD-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemotherapy in Metastatic Bladder Cancer TGF-b And PD-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemordiation TheRapy The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma Tisellizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma Tiselizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC Tiselizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy in Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy in Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy in Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy in Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy in Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy in Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy in Patients With Small Cell Carcino	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	https://ClinicalTrials.gov/show/NCT0492994 https://ClinicalTrials.gov/show/NCT0492904 https://ClinicalTrials.gov/show/NCT0492904 https://ClinicalTrials.gov/show/NCT0492904 https://ClinicalTrials.gov/show/NCT0492904 https://ClinicalTrials.gov/show/NCT0491256 https://ClinicalTrials.gov/show/NCT04997856 https://ClinicalTrials.gov/show/NCT04997856 https://ClinicalTrials.gov/show/NCT0497856 https://ClinicalTrials.gov/show/NCT04907856 https://ClinicalTrials.gov/show/NCT04907856 https://ClinicalTrials.gov/show/NCT04907856 https://ClinicalTrials.gov/show/NCT04050737 https://ClinicalTrials.gov/show/NCT04907856 https://ClinicalTrials.gov/show/NCT04907856 https://ClinicalTrials.gov/show/NCT049078568 https://ClinicalTrials.gov/show/NCT04061928 https://ClinicalTrials.gov/show/NCT04061928 https://ClinicalTrials.gov/show/NCT04061928 https://ClinicalTrials.gov/show/NCT04061928 https://ClinicalTrials.gov/show/NCT0447326 https://ClinicalTrials.gov/show/NCT0447326 https://ClinicalTrials.gov/show/NCT0447326 https://ClinicalTrials.gov/show/NCT0447326 https://ClinicalTrials.gov/show/NCT0447326 https://ClinicalTrials.gov/show/NCT0447326 https://ClinicalTrials.gov/show/NCT0447326 https://ClinicalTrials.gov/show/NCT0471694716495

Checkpoint inhibitor	Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma	Υ		https://ClinicalTrials.gov/show/NCT03737123
Checkpoint inhibitor	Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer	Y	Y	https://ClinicalTrials.gov/show/NCT02586610
Checkpoint inhibitor	Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients  TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After	Y	Y	https://ClinicalTrials.gov/show/NCT03921684
Checkpoint inhibitor	Chemo-radiation (ATOMICC)	Y	Y	https://ClinicalTrials.gov/show/NCT03833479
Checkpoint inhibitor Checkpoint inhibitor	TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers	Y	Y	https://ClinicalTrials.gov/show/NCT03955978 https://ClinicalTrials.gov/show/NCT04306900
Checkpoint inhibitor	TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With	Y		https://ClinicalTrials.gov/show/NCT03884556
Charles intintities	Advanced Cancers Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for	Y		https://ClinicalTrials.com/sham/NCT02246642
Checkpoint inhibitor	Relapsed/Refractory PMBCLs			https://ClinicalTrials.gov/show/NCT03346642
Checkpoint inhibitor	CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab	Y		https://ClinicalTrials.gov/show/NCT03638141
Checkpoint inhibitor	Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)		Y	https://ClinicalTrials.gov/show/NCT03354962
Checkpoint inhibitor	REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer	Υ		https://ClinicalTrials.gov/show/NCT03515629
Checkpoint inhibitor	Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the		Y	https://ClinicalTrials.gov/show/NCT04795297
Checkpoint inhibitor	Treatment of Metastatic Solid Malignancies  Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma		Y	https://ClinicalTrials.gov/show/NCT04785287 https://ClinicalTrials.gov/show/NCT03116529
Checkpoint inhibitor	A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced	Y	'	https://ClinicalTrials.gov/show/NCT05235542
Checkpoint inhibitor	Malignant Tumors  AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer	Y		https://ClinicalTrials.gov/show/NCT05430906
Checkpoint inhibitor	NBTXR3, Radiation Therapy, Ipilimumab, and Nivolumab for the Treatment of Lung and/or Liver		Υ	https://ClinicalTrials.gov/show/NCT05039632
Checkpoint inhibitor	Metastases From Solid Malignancy Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer	Y	·	https://ClinicalTrials.gov/show/NCT03249142
Checkpoint inhibitor	Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With		Υ	https://ClinicalTrials.gov/show/NCT03601455
Checkpoint inhibitor	Unresectable, Locally Advanced, or Metastatic Bladder Cancer  Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer		Y	https://ClinicalTrials.gov/show/NCT03150836
Checkpoint inhibitor	Tremelimumab With Chemoembolization or Ablation for Liver Cancer	Y		https://ClinicalTrials.gov/show/NCT01853618
Checkpoint inhibitor	Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer	Y		https://ClinicalTrials.gov/show/NCT02962063
Checkpoint inhibitor	Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation		Υ	https://ClinicalTrials.gov/show/NCT02962063
·	Before Surgery for Esophageal Cancer  Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant	Y		
Checkpoint inhibitor	to Chemotherapy Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic			https://ClinicalTrials.gov/show/NCT03457142
Checkpoint inhibitor	Cancer	Y		https://ClinicalTrials.gov/show/NCT04324307
Checkpoint inhibitor	Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC	Υ		https://ClinicalTrials.gov/show/NCT04043195
Checkpoint inhibitor	Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer		Y	https://ClinicalTrials.gov/show/NCT02868632
Checkpoint inhibitor	Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced		Y	https://ClinicalTrials.gov/show/NCT03799445
Спескропп пппыног	Oropharyngeal Squamous Cell Carcinoma  The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell		'	maps.//climicarmais.gov/silow/NC 1037 99443
Checkpoint inhibitor	Lung Cancer	Y		https://ClinicalTrials.gov/show/NCT01331525
Checkpoint inhibitor	Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer		Y	https://ClinicalTrials.gov/show/NCT02311361
Checkpoint inhibitor	Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell	Y		https://ClinicalTrials.gov/show/NCT02716805
Checkpoint inhibitor	Transplant Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer	Y		https://ClinicalTrials.gov/show/NCT02735239
Checkpoint inhibitor	Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas	Υ		https://ClinicalTrials.gov/show/NCT05133505
Checkpoint inhibitor	An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or	Y		https://ClinicalTrials.gov/show/NCT03662659
	Gastroesophageal Junction (GEJ) Cancers  IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast			
Checkpoint inhibitor	Carcinoma	Y		https://ClinicalTrials.gov/show/NCT02614833
Adoptive T cell	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20	Υ		https://ClinicalTrials.gov/show/NCT03097770
Adoptive T cell	Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases	Y		https://ClinicalTrials.gov/show/NCT04037241
Adoptive T cell	alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based	Υ		https://ClinicalTrials.gov/show/NCT03692429
Adoptive T cell	CYAD-101 Chimeric Antigen Receptor T-cells  Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B	Y		https://ClinicalTrials.gov/show/NCT03929107
	Cell Lymphoma.  CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1			
Adoptive T cell	Positive Multiple Myeloma	Y		https://ClinicalTrials.gov/show/NCT03710421
Adoptive T cell	Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia	Υ		https://ClinicalTrials.gov/show/NCT02588456
Adoptive T cell	Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation	Υ		https://ClinicalTrials.gov/show/NCT04691284
Adoptive T cell	Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia	Y		https://ClinicalTrials.gov/show/NCT02822326
Adoptive T cell	Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy	Y		https://ClinicalTrials.gov/show/NCT01735604
Adoptive T cell	Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory	Y		https://ClinicalTrials.gov/show/NCT02965157
Adoptive T cell	CD20+ Lymphoma  Radiation Post-CAR T in Refractory Lymphoma		Y	https://ClinicalTrials.gov/show/NCT04473937
Adoptive T cell	Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen		Y	https://ClinicalTrials.gov/show/NCT05336383
	Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma  Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic		Y	
Adoptive T cell	Malignancies		Y	https://ClinicalTrials.gov/show/NCT04888338
	Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating	Y		https://ClinicalTrials.gov/show/NCT03450122
Adoptive T cell	Participants With Advanced or Recurrent Sarcoma			1
Adoptive T cell	Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or	Υ		https://ClinicalTrials.gov/show/NCT00499577
· ·	Stem Cell Transplant. Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiplie Myeloma Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB	Y		https://ClinicalTrials.gov/show/NCT00499577 https://ClinicalTrials.gov/show/NCT00871689
Adoptive T cell	Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma			https://ClinicalTrials.gov/show/NCT00871689
Adoptive T cell	Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular	Y	Y	
Adoptive T cell  Adoptive T cell  Adoptive T cell	Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma	Y	Y	https://ClinicalTrials.gov/show/NCT00871689 https://ClinicalTrials.gov/show/NCT00003552